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1. INTRODUCTION         
The oral route of drug administration is the most important method for administering 
drugs for systemic effects. Except in certain cases the parenteral route is not routinely used 
for self administration, e.g. insulin. The topical route of administration has only recently been 
employed to deliver drugs to the body for systemic effects. The parenteral route of 
administration is important in treating medical emergencies in which the subject is comatose 
or cannot swallow. Nevertheless it is probable that at least 90% of all drugs used to provide 
systemic effects are administered by the oral route. When a new drug is discovered one of the 
first questions, a pharmaceutical company asks is whether or not the drug can be effectively 
administered forits intended effect by the oral route. Of drugs that are administered orally, 
solid oral dosage forms represent the preferred class of products. Tablets and capsules 
represent unit dosage forms in which usual dose of a drug has been accurately placed.  
 
1.1 TABLETS: 1 
 
Tablets are solid preparation each containing a single dose of one or more active 
ingredients and are obtained by compressing uniform volumes of particles. The objective of 
the design and manufacture of the compressed tablet is to deliver orally the correct amount of 
drug in the desired location and to have its chemical integrity protected to the point. 
Tablets may vary in size, shape, weight, hardness, thickness, and disintegration 
characteristics and in other aspects, depending upon the intended use of the tablets and their 
method of manufacture.  
 
1.2 TYPES OF TABLETS 
 
1. Tablets ingested orally. e.g. standard compressed tablets, enteric coated tablets, delayed 
release tablets and mouth dissolving tablets  
2. Tablets used in the oral cavity. e.g. buccal and sublingual tablets,  
3.  Tablets used to prepare solution. e.g. effervescent tablets  
4. Tablets administered through other routes. e.g. vaginal tablets and implants  
 
Recently Oro dispersible Drug Delivery Systems have started gaining popularity and 
acceptance as New Drug Delivery Systems.2 
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 Since the development cost of a new chemical entity is very high, the Pharmaceutical 
companies are focusing on the development of new drug delivery systems for existing drug 
with an improved efficacy and bioavailability together with reduced dosing frequency to 
minimize side effects. 
 
Dysphagia (Difficulty in Swallowing) is seen to afflict nearly 35% of the general 
population and is common with all age groups.  This disorder is also associated with number 
of medical conditions including stroke, Parkinson’s disease, Aids, Head and neck radiation 
therapy and other neurological disorders including Cerebral palsy.3 
 
Swallowing of solid dosage forms like Tablets / Capsules and improper dosing of 
suspension / emulsion may precipitate patient noncompliance with young individuals because 
of under developed muscular and nervous systems, psychiatric patients, non-cooperative 
patients and travellers who have little access to water.4 
 
The approach to overcome these problems can be done by Formulating Oro 
dispersible  Tablets. 
 
1.3 HISTORICAL DEVELOPMENT OF FAST DISSOLVING TABLETS 
Difficulty in swallowing (Dysphagia) is a common problem in all age groups, 
especially the elderly and pediatrics, because of physiological changes associated with these 
age groups. It is common to see those afflicted carrying a small device with them, which is 
used for crushing tablets, enabling easy ingestion. Other categories that experience problems 
using conventional oral dosage forms include are the mentally ill, uncooperative and 
nauseated patients, those with conditions of motion sickness, sudden episodes of allergic 
attack and coughing. Sometimes, it may be difficult to swallow conventional products due to 
unavailability of water. These problems led to the development of a novel type of solid oral 
dosage form called mouth-dissolving tablets, which disintegrate and dissolve rapidly in saliva 
without the need of the water. They are also known as Oro dispersible  tablets, melt-in-mouth 
tablets, rapimelts, porous tablets, oro-dispersible, quick dissolving or rapidly disintegrating 
tablets.  
 
 Since 1986 when the Zydis® lyophilized, fast-dissolving dosage forms were first 
introduced, a number of other fast-dissolving formulations were developed, and the 
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technology is still improving. Using the concept of Gregory et al., Scherer has patented the 
Zydis technology. Using the freeze-drying process, this technology converts the mixture of 
active ingredient and water dispersible carrier materials into open matrix network that 
disintegrates rapidly. 
  
           The network is highly porous solid form, which allows rapid penetration of liquid and 
facilitates quick disintegration of the dosage unit. The freeze-drying approach produces the 
fastest dissolving tablets, but the process is expensive, and the resulting tablets are 
mechanically weak. The other most widely used method to manufacture these tablets is via 
regular compression that can produce tablets with higher mechanical strengths. The 
disintegration or melting time of the compressed tablets is not as fast as the freeze-dried 
dosage forms, but the compressed tablets provide many advantages, such as high mechanical 
strength facilitating their handling and processing. The technology of the compressed tablets 
is also making major improvements, producing tablets that can melt within several seconds in 
the mouth.  
 
The fast-melting tablets present the combined benefits of a liquid formulation and a 
solid dosage form. They are easy to handle and ingestible as a liquid dosage form. An ideal 
fast-melting tablet should possess the following characteristics. The tablet should melt or 
disintegrate in the mouth within 60 seconds. The tablets should also be mechanically strong 
for easier handling, and the production cost should be similar to that of conventional tablets. 
The use of existing tablet machinery and procedures dictates the low production cost and has 
another advantage of producing mechanically strong tablets. The ideal fast-melting tablets 
should also be less sensitive to humidity, thus allowing multi-tablet packaging. 
 
 
1.4  ORO DISPERSIBLE TABLETS5 
Oro dispersible tablets are uncoated tablets intended to be placed in the mouth where 
they disperse rapidly before being swallowed. 
 
1.4.1 DIFFICULTIES WITH EXISTING ORAL DOSAGE FORM6 
 Patient may suffer from tremors therefore they have difficulty to take powder and 
liquids .In dysphagia physical obstacles and adherence to an esophagus may cause 
gastrointestinal ulceration. 
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 Swallowing of solid dosage form like tablet and capsules may produce difficulty for 
young adult of incomplete development of muscular and nervous system and elderly 
patients suffer from dysphagia. 
 Liquid medicaments (suspension and emulsion) are packed in multidose container; 
therefore achievement of uniformity in the content of each dose may be difficult. 
 Buccal and sublingual formation may cause irritation to oral mucosa, so patients 
refused to use such medications. 
 Cost of products is main factor as parenteral formulations are most costly and 
discomfort. 
 
1.4.2 ADVANTAGES OF ORO DISPERSIBLE  DOSAGE FORM7 
Ease of administration for patients who are mentally ill, disabled and uncooperative. 
 Requires no water intake. 
 Quick disintegration and dissolution of dosage form. 
 Overcomes unacceptable taste of the drugs. 
 Can be designed to leave minimal or no residue in the mouth after administration and 
also to provide a pleasant mouth feel. 
 Allows high drug loading. 
 Faster onset of action. 
 Convenient - ideal dosage form when fast relief required, for example, pain relief, 
migraine, or allergy. 
 New business opportunities; line extension exclusivity of product promotion and 
patient life extension. 
 
1.4.3 Requirements of Oro dispersible  Tablets (ODT’s)  2 
1. Ease of Administration: 
It should be easy to administer and handle for geriatrics and paediatrics. 
2. Taste of  the Medicament: 
It should include substances that would mask the bitter taste of the 
medicament, because the tablet dissolve or disintegrate in patient’s mouth thus 
releasing the active ingredients which would come in contact with the taste buds 
and hence taste masking of the drug becomes critical to patients compliance. 
 
																																																																																			INRODUCTION																							
 
DEPARTMENT	OF	PHARMACEUTICS,	K.M.C.P	 Page	5	
 
3. Hygroscopicity: 
Since several Oro dispersible  dosage forms are hygroscopic, they cannot 
maintain physical integrity under normal condition form humidity which calls for 
specialized product packaging. 
4. Friability: 
In order to allow ODT’s to dissolve in the mouth, they are made of either very 
porous and soft moulded matrices or compressed into tablets with very low 
compression force which makes the tablets friable and / or brittle which are 
difficult to handle often requiring specialized peel-off blister packing. 
5. Mouth feel: Presence of any large particles from the disintegrating tablet that are 
insoluble or slowly soluble in saliva would lead to an unpleasant gritty feeling.  In 
such cases, flavours can be used which provides improved mouth fell perception. 
6. Requires no water intake for administration. 
7. They should allow high Drug loading. 
8. They should leave minimal or no residue in the Mouth. 
9. They should be manufactured using conventional tablets processing and 
packaging equipment at low cost. 
 
1.4.4 Salient Features of Oro dispersible  Tablets (ODT’s)2, 8 
Ease of administration for patients who are mentally ill, disabled and unco-operative. 
1. No risk of choking. 
2. Requires no water intake. 
3. Overcomes unacceptable taste of the Drugs. 
4. Allows high drug loading. 
5. It leaves minimal or no residue in the mouth after administration. 
6. Quick disintegration and dissolution of the dosage form. 
7. Facilitates faster onset of therapeutic action. 
8. Improved Bioavailability can be achieved. 
9. Avoids First Pass Metabolism due to Pregastric absorption. 
10. Enhanced Patient compliance. 
11.  Ability to provide advantages of liquid medication in the form of solid preparation. 
12. Adaptable and ameanable to existing processing and packaging machinery. 
13. Cost effective. 
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14. Rapid drug therapy intervention is possible. 
15. Free of the risk of suffocation due to physical obstruction when swallowed thus 
offering  improved safety. 
16. Enhanced stability. 
17. Optimum versatility with low manufacturing cost. 
18. Ideal dosage form for Peadiatric and geriatric patients. 
19. Promote New Business Opportunities like Product differentiation, Product – 
promotion, Patient extension and life cycle management. 
 
1.4.5 Biopharmaceutical Considerations for Oro dispersible  Tablets 4 
 When a new drug delivery system is introduced, Biopharmaceutical factors like 
Metabolism and Excretion must be considered. 
 
Pharmacokinetics: 
 After absorption, the drug attains therapeutic level and elicits pharmacological effect.  
So both rate and extent of absorption is important. 
 
In conventional dosage forms, there is delay in disintegration and dissolution while 
ODT  rapidly disintegrates in oral cavity and dissolution is fast. 
 
Due to disintegration of ODT in mouth, absorption is started from mouth, phargnx 
and oesophagus.  Some factors like age, gastro intestinal pH, blood flow through GIT are 
taken into consideration because elderly be considered as seperate unique medicate 
population. 
1.Drug Disintegration: 
It depends on factors like 
 Tissue permeability 
 Perfusion rate 
 Binding of drug to tissues 
 Disease state 
 Drug interactions 
 
In Geriatric patients decrease in lean body mass and total body water result in decreased 
volume of distribution (Vd) of lipid soluble drugs. 
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2. Duration and Intensity of action: 
It depends on factors like 
 Bio transformation 
 Decrease in liver volume 
 Regional blood flow to liver 
 
Decrease in liver volume and regional blood flow to liver reduces the 
biotransformation of drug through oxidation, reduction and hydrolysis.  Excretion by renal 
clearance is slowed, thus half life of renally excreted drugs increased. 
 
1.4.6 Bioavailability of Oro dispersible  Tablets (ODT’s) 9  
Disintegration and dissolution of ODT in oral cavity depends upon various factors like 
 Method of manufacture 
 Ingredients used for taste masking 
 Physicochemical properties of the drug 
 
While manufacture, batch to batch consistency should be ensured, patient’s factors are 
also involved such as presence of amount of saliva in oral cavity and the extent of tongue 
movements etc., 
The disintegration time in-vivo can vary greatly depending on how the patient 
processes the drug product.  The patient who actively moves the drug product with the tongue 
around the oral cavity experiences shortest disintegration time. 
 
1.5  General Properties Of ODT’s 10 
1) Excellent Mouth Feel  
 Disintegrants has narrow particle size distribution that imparts a smooth mouth feel to 
quick dissolve. Large particles tend to result in a gritty mouth feel that many consumers find 
objectionable. Therefore, smaller particles which are not felt in the mouth are preferred. 
These benefits are especially important in ODT. 
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2) Taste Masking 8  
Table: 1 Approaches have been taken to mask the unpleasant taste of drugs 
Sensory approaches * Using flavoring & sweetening agents  
* Inhibiting bitterness 
* Numbing of taste buds 
Complexation & adsorption * Complexation with Ion-exchange resins 
* Formation of Inclusion complexes with  
cyclodextrin derivatives 
* Adsorption of drugs onto clays or other  
adsorbents 
* Wax embedding of drugs 
Chemical approaches * Formation of Prodrugs 
* Formation of different Salts 
Barrier approaches * Using Viscosity modifiers 
* Using Emulsions 
* Using Liposomes 
* Using Microspheres 
 
3.Fast Disintegration  
 When introduced into water, disintegrant which is used in ODT’S, quickly wicks 
water into its capillaries and swells which results in rapid disintegration. The disintegrant 
particles are granular and highly porous. This porous particle morphology allows for better 
wicking of liquid into the particle and tablet. This sugar disintegrant polymers does not form 
gels which could retard drug release or result in a gummy texture. 
 
 
4) Tablet Hardness 
 To achieve rapid disintegration, ODT’s are often porous and/or have low hardness 
and high friability. As a result, there can be a high level of tablet breakage unless special 
packaging systems are used. Therefore the challenge is to develop formulations with rapid 
disintegration and robust physical properties. Due to its unique particle morphology, the 
super disintegrant is a highly compressible material that increases tablet hardness and reduces 
friability. 
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 ODT’S system comprises a low moisture that is convenient for doing, suitable for 
labelling and easy packing, handling and application. At the same time the rapid hydration 
rate facilitates an almost immediate softening of the ODT’S upon application in the oral 
cavity. The friability and strength of the tablet may be selected/modified to facilitate 
automatic rewinding, die punching and packaging during manufacturing. 
 
1.6 SUPER DISINTEGRENTS11 
A disintegrant is an excipient, which is added to a tablet or capsule blend to aid in the 
breakup of the compacted mass when it is put into a fluid environment.  
 
Table: 2 
List of super disintegrants and their mechanism of action 
 
Name of disintegrant Brand Name Concentration (%) 
Mechanism of 
action 
Sodium Starch 
Glycolate 
Explotab, Primogel 2-8%  Swelling  
Micro Crystalline 
Cellulose  
Avicel, Celex 2-15%  Water wicking  
Cross linked povidone Crospovidone 2-5%  Water wicking, 
swelling  
Low substituted 
Hydroxy Propyl 
Cellulose  
LH-11, LH-12 
(Grades)  
1-5%  Swelling  
Crosscaramellose 
sodium  
Ac-Di-Sol  1-3% - direct 
compression 2-4% 
- wet granulation  
Wicking and 
swelling  
Pre gelatinized Starch  Starch 1500  1-20%  Swelling  
 
Advantages: 
1. Effective in lower concentrations. 
2. Less effect on compressibility and flow ability. 
 
1.7  MECHANISM OF ACTION: 
There are four major mechanisms for tablets disintegration as follows  
1. Swelling: 
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2. Porosity and capillary action (Wicking):  
Effective disintegrants that do not swell are believed to impart their disintegrating 
action through porosity and capillary action. When we put the tablet into suitable aqueous 
medium, the medium penetrates into the tablet and replaces the air adsorbed on the particles, 
which weakens the intermolecular bond and breaks the tablet into fine particles. Tablet 
porosity provides pathways for the penetration of fluid into tablets. The disintegrant particles 
(with low cohesiveness &compressibility) themselves act to enhance porosity and provide 
these pathways into the tablet (Figure 2).Water uptake by tablet depends upon hydrophilicity 
of the drug /excipient and on tableting conditions. For these types of disintegrants 
maintenance of porous structure and low interfacial tension towards aqueous fluid is 
necessary which helps in disintegration by creating a hydrophilic network around the drug 
particles. 
 
3. Disintegrating particle/particle repulsive forces:  
Another mechanism of disintegration attempts to explain the swelling of tablet made 
with “non-swellable” disintegrants. Guyot-Hermann has proposed a particle repulsion theory 
based on the observation that non-swelling particle also cause disintegration of tablets (Figure 
3). The electric repulsive forces between particles are the mechanism of disintegration and 
water is required for it. Researchers found that repulsion is secondary to wicking. 
 
Deformation: 
During tablet compression, disintegrated particles get deformed and these deformed 
particles get into their normal structure when they come in contact with aqueous media or 
water. Occasionally, the swelling capacity of starch was improved when granules were 
extensively deformed during compression. This increase in size of the deformed particles 
produces a breakup of the tablet (Figure 4). Starch grains are generally thought to be “elastic” 
in nature meaning that grains that are deformed under pressure will return to their original 
shape when that pressure is removed. But, with the compression forces involved in tableting, 
these grains are believed to be deformed more permanently and are said to be “energy rich” 
with this energy being released upon exposed to water. 
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Mechanism of Drug Release from ODT’s 9 
 The drug releases from the ODT’S due to the action of super disintegrants like cros 
povidone, cros carmellose sodium, sodium Starch glycollate and polyvinyl pyrrolidone in the 
formulation. 
 superdisintegrants provide quick disintegration due to combined effect of swelling 
and water absorption by the formulation. As an effect of swelling of superdisintegrant, the 
wetted surface of the carrier increases, which promotes wettability and dispersibility of the 
system and thereby enhance the disintegration and dissolution. 
 
1.8 Basic Approaches Of Designing ODT’s  1, 2, 4 
 To ensure the tablets Oro dispersible  attribute, water must quickly egress into the 
tablet matrix to cause rapid disintegration and instantaneous dissolution of the tablet. This can 
be achieved by 
a. Maximizing the porous structure of the tablet matrix 
b. Incorporating the appropriate disintegrating agent 
c. Using highly water soluble excipients in the formulation. 
 
Conventional Techniques 
1) Tablet moulding 
2) Direct compression 
3) Spray drying 
4) Sublimation 
5) Freeze drying (or) Lyophilization 
6) Mass extrusion 
7) Taste masking 
8) Use of sugar based excipients 
 
1) Tablet Moulding: 
 Moulded tablets are usually prepared by different moulding techniques. 
 
A. Compression moulding: 
 The powder mixture previously moistened with a solvent like ethanol/water is 
compressed into mould plates to form a wetted mass. 
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B. Heat moulding: 
 The moulded forms can be obtained directly from a molten matrix in which the drug 
is dispersed / dissolved. 
 
C. No vacuum Lyophilization: 
 In this process at standard pressure the solvent from a drug solution or suspension is 
evaporated. 
 
 Tablets produced by moulding are solid dispersion. Moulded tablets disintegrate more 
rapidly and offer improved taste because the dispersion matrix is in general made from water 
soluble sugars. The active ingredients in most cases is absorbed through the mucosal lining of 
the mouth.1 The tablets prepared by moulding offer more rapid disintegration and improved 
taste as the dispersion matrix is made from water soluble excipients (sugars).4 
 
 Moulded tablets typically do not possess great mechanical strength. Erosion and 
breakage of the moulded tablet often occur during handling and opening of blister packs.1 
 
2) Direct Compression 
 It is the easiest way to manufacture tablets. Low manufacturing cost, conventional 
equipments, commonly available excipients and a limited number of processing steps lead 
this technique to be a preferable one. High doses can be accommodated and final weight of 
tablet can easily exceed that of other production methods. 
 
 Addition of disintegrants in ODT’s leads to quick disintegration of tablets and hence 
improves dissolution. In many Oro dispersible  tablet technologies based on direct 
compression, the disintegrants principally affect the rate of disintegration and hence the 
dissolution. 
 
 The disintegration and dissolution of directly compressed tablets depend on single or 
combined effect of disintegrant, water soluble excipients and effervescing agents.The 
optimum concentration of superdisintegrant can be selected according to critical 
concentration of the disintegrant. Below this concentration the tablet disintegration time is 
inversely proportional to the concentration of superdisintegrant, whereas if concentration of 
superdisintegrant incorporated in tablet is above the critical concentration, the disintegration 
time remains approximately constant or even increases. 
																																																																																			INRODUCTION																							
 
DEPARTMENT	OF	PHARMACEUTICS,	K.M.C.P	 Page	15	
 
 
3) Spray Drying 
 Spray drying technique produces highly porous and fine powders as the processing 
solvent is evaporated during the process. This technique is based upon a particulate support 
matrix that is prepared by spray drying an aqueous composition containing support matrix 
and other components to form a highly porous and fine powder. This is then mixed with 
active ingredient and compressed into tablet, which disintegrated in less than 20 seconds 
when immersed in an aqueous medium. 
 
4) Sublimation  
 Compressed tablets composed of water soluble excipients as tablet matrix often do not 
dissolve rapidly due to low porosity. ODT’S having porous structure and sufficient 
mechanical strength, which dissolves quickly have been developed using urea, ammonium 
carbonate, camphor, naphthalene, tablet excipients and finally compressed the blend. Porous 
structure is generated by sublimation of volatile oil. 
 
5) Freeze Drying / Lyophilization  
 A process in which water is sublimated from the product after freezing is called 
Freeze drying. 
 
 Lyophilization results in preparations which are highly porous with a very high 
specific surface area, which dissolve rapidly and show improved absorption and 
bioavailability. 
 
 The use of Freeze drying is limited due to high cost of the equipment and processing. 
Other major disadvantages of the final dosage forms include lack of physical resistance in 
standard blister packs. 
 
6) Mass Extrusion  
 This technology involves softening the active blend using the solvent mixture of water 
soluble polyethylene glycol, using methanol and expulsion of softened mass through the 
extruder or syringe to get a cylinder of the product into even segments using heated blade to 
form tablets. The dried cylinder can also be used to coat granules of bitter tasting drugs and 
thereby masking their bitter taste. 
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7) Taste Masking: 
 Taste masking is an essential requirement for Melt-in-Mouth Tablets for commercial 
success. 
 Drugs with unacceptable bitter taste can be microencapsulated into pH sensitive 
acrylic polymers like Eudragit E, Eudragit L-55 and Eudragit RL. 
 
8) Use Of Sugar Based Excipients  
 Sugar based excipients (eg : sorbitol, mannitol, dextrose, xylitol, fructose etc) have 
been used as bulk agents. Aqueous solubility and sweetness impart pleasing mouth feel and 
good taste masking. But no sugar based materials have fast dissolution rate and good 
compressibility and/or compactibility. However technologies are developed to make use of 
the sugar based excipients in the design of ODT’s. 
 
1.9 PATENTED TECHNOLOGIES 1, 4, 5 
1) Zydis Technology: 
 Zydis is a unique freeze dried oral solid dosage form that can be swallowed without 
water as it dissolves instantly on tongue in less than 3 seconds. A zydis tablet is produced by 
lyophilizing or freeze drying the drug in a matrix usually consisting of gelatin, dextran or 
alginates. Water is used during the process to produce porous units for rapid disintegration. 
The zydis formulation is also self preserving because the final water concentration in the 
freeze dried product is too low to allow for microbial growth. 
 
 A major claim of the zydis product is increased bioavailability because of its 
dispersion and dissolution in saliva while still in the oral cavity, there can be a substantial 
amount of Pregastric absorption from this formulation. 
 
 The product is very light weight and fragile and must be dispensed in a special 
peelable blister pack. The zydis formulation has poor stability at higher temperatures and 
humidities. It readily absorbs water and is very sensitive to degradation at humidities greater 
than 65%. 
 
2) Orasolv Technology 
 It is CIMA lab’s first Oro dispersible  formulation. The tablets are prepared by direct 
compression technique at low compression force inorder to minimize oral disintegration and 
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dissolution time. Orasolv technology is an example of slightly effervescent tablet that rapidly 
dissolves in mouth. The active medicament is taste masked and dispersed in saliva due to the 
action of effervescent agents. It provides a pleasant sensation of effervescence in mouth of 
the patient. Their disintegration time is less than 30 seconds. The major disadvantage of 
orasolv technology is its low mechanical strength. The tablets produced are soft and friable 
and need to be packed in specially designed pack. 
 
3) Durasolv Technology  
 Durasolv is the patented technology of CIMA labs. The tablets made by this 
technology consist of a drug, fillers and a lubricant. Tablets are prepared by using 
conventional tabletting equipment and have good rigidity. These can be packed into 
conventional packaging system like blisters. It is an appropriate technology for products 
requiring low amounts of active ingredients. 
 
4) Wowtab Technology  
 It is patented by Yamanouchi. Wow means “without water” In this process, the active 
ingredient is mixed with a low mouldability saccharide and granulated with  
a high mouldability saccharide and compressed to obtain a rapidly melting strong tablet. The 
wowtab product dissolves quickly in 15 seconds or less. 
 
5) Flash Dose Technology (Ceform Technology)  
 It is patented by Fusiz laboratories. It utilizes a unique spinning mechanism to 
produce a floss like crystalline structure, much like cotton candy. This crystalline sugar can 
incorporate the active drug then compressed into a tablet. The final product has a very high 
surface area for dissolution. Once placed on the tongue it disperses and dissolves quickly. 
 
6) Flash Tab Technology  
 It is patented by Prographarm labs. It utilizes most of the same excipients as in 
conventional compressed tablets. A disintegrating agent and a swelling agent are used in 
combination with coated drug particles in this formulation to produce a tablet that 
disintegrates in mouth within one minute. This technology utilizes the conventional tabletting 
technology. 
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7) Oraquick Technology  
 The Oraquick Oro dispersible  tablet formulation utilizes a patented taste masking 
technology by K.V. Pharmaceutical company, who claim that its taste masking  technology 
i.e Microsphere technology (Micromask) has superior mouth feel over taste masking 
alternatives. The taste masking process does not utilize solvents of any kind and therefore 
leads to faster and more efficient production. Tablets with significant mechanical strength 
without disrupting taste masking are obtained after compression. Oraquick claims quick 
dissolution in a matter of seconds with good taste masking. 
 
8) Quick-Dis Technology  
 It is a novel intra oral Oro dispersible  drug delivery system invented by Lavipharm 
Laboratories. It is a thin, flexible and quick dissolving film placed on the top or the floor of 
the tongue. It is retained at the site of application and rapidly releases the active agent for 
local and/or systemic absorption. It can be packed in unit dose pouches to multiple dose 
blister packages. 
 
 For a quick diss film of thickness 2mm, the disintegration time is 5-10 seconds and 
the dissolving time is around 30 seconds in aqueous media. The typical release profile of an 
active ingredient exhibited by this system is 50% released within 30 seconds and 95% within 
1 minute. 
 
9) Nanocrystal Technology  
 Nanocrystal particles are small particles of drug substance, typically less than 1000 
nanometers (nm) in diameter which are produced by milling the drug substance using wet 
milling technique. This technology provides for cost effective manufacturing processes that 
utilize conventional, scalable unit operations, wide range of doses (upto 200mg of API per 
unit), use of conventional, compendial inactive components and employment of non moisture 
sensitive inactives. 
 
 Nano crystal colloidal dispersions of drug substance are combined with water soluble 
ingredients, filled into blisters and lyophilized. The resultant wafers are remarkably robust yet 
dissolve in very small quantities of water in seconds. 
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1.10  LIST OF PRODUCTS CATEGORIZED BY TECHNOLOGY 
 
ZYDIS PRODUCTS12 
Claritin Reditab 
Micronized loratadine (10 mg), citric acid, gelatin, mannitol, mint flavor. 
 
Feldene Melt 
Piroxicam (10 or 20 mg), gelatin, mannitol, aspartame, citric anhydrous  
 
Maxalt-MLT 
Rizatriptan (5 or 10 mg), gelatin, mannitol, aspartame, peppermint flavor 
 
Pepcid RPD 
Famotidine (20 or 40 mg), gelatin, mannitol, aspartame 
 
ZyprexaZydis 
Olanzapine (5, 10, 15 or 20 mg), gelatin, mannitol, aspartame, methylparaben sodium, 
propylparaben sodium  
 
Zofran ODT 
Ondansetron (4 or 8mg), aspartame, gelatin, mannitol, methlparaben sodium, propylparaben 
sodium, strawberry flavour. 
 
Dimetapp Quick Dissolve Chidern’s Cold and Allergy Tablets (OTC) 
Active ingredient: Loratadine. 
 
ORASOLV PRODUCTS 
RemeronSoltab 
Mirtazepine (15, 30, or 45 mg), aspartame, citric acid, crospovidone, hydroxypropyl 
methylcellulose, magnesium stearate, mannitol, microcrystalline cellulose, polymethacrylate, 
povidone, sodium bicarbonate, starch, sucrose, orange flavor. 
 
TempraFirstTabs 
Acetaminophen (80 or 160 mg), inactive ingredients including mannitol (currently available 
in Canada). 
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DURASOLV PRODUCTS 
NuLev 
Hyoscyamine sulfate (0.125 mg), aspartame, colloidal silicon dioxide, crospovidone, mint 
flavoring, magnesium stearate, mannitol, microcrystalline cellulose 
 
Zomig ZMT 
Zolmitriptan (2.5 mg),mannitol, microcrystalline cellulose, crospovidone, aspartame, sodium 
bicarbonate, citric acid, anhydrous, colloidal silicon dioxide, magnesium stearate, orange 
flavor 
 
Triaminic Softchew(OTC) 
Active ingredients: Chlorpheniramine, Dexomethorphan. 
 
WOWTAB PRODUCTS 
Benadryl Allergy & Sinus Fastmelt (OTC) 
Active ingredients: Diphenhydramine citrate, pseudophidrine HCL. 
 
Children's Benadryl Allergy & Cold Fastmelt (OTC) 
Active ingredients: Diphenhydramine + Pseudoephidrine (12.5mg+30mg, 19mg+30mg). 
 
Table No: 3 
MARKETED FORM OF ORO DISPERSIBLE  TABLETS13 
 
Technologies Trade Name Ingredient Category Manufacturer 
Freeze 
Drying 
 
 
 
 
 
 
 
 
 
 
 
 
Disintegrant 
Addition 
Feldene Fast 
melt 
Claritin Redi 
Tab 
MaxaltMLT 
Zyprexia 
Pepeid RPD 
Zofran CDT 
 
Zornig-ZMT 
 
ZelaparTM 
TempraQuicklets 
Febrectol 
 
Nimulid MDT  
Piroxicam 
 
Loratidine 
 
Rizatriptan 
Olanzapine 
 
Famotidine 
Ondansetron 
 
Zolmitriptan 
 
Selegilline 
Acetaminophen 
 
Paracetamol 
Antirheumatic 
non-steroidal 
Antihistamine 
 
Antimigraine 
Antipsychotic 
 
Antihistamine 
5-HT3 
Antagonist 
 
Antimigraine 
 
Antipsychotic 
 
Antipyretic 
Pfizer Inc., NY, 
USA 
 
Schering Plough 
Corp., 
Kenilworth, 
USA 
Merck & Co., 
NJ, USA 
Eli LiIIy, 
Indianapolis, 
USA. 
Merck & Co., 
NJ, USA 
GlaxoWellcome, 
Middlesex, UK 
																																																																																			INRODUCTION																							
 
DEPARTMENT	OF	PHARMACEUTICS,	K.M.C.P	 Page	21	
 
 
 
 
 
 
 
 
 
 
 
Sugar Based 
Excipient 
 
Torrox MT 
 
Olanexlnstab 
 
Romilast 
Benadryl 
Fastmett 
 
Nimesulide 
 
Rofecoxib 
 
Olanzapine 
 
Montelukast 
 
Diphenhydramine 
& 
Pseudoephedrine 
 
 
Antipyretic 
 
Antipyretic 
 
COX-2 
Inhibitor 
NSAID 
Antipsychotic 
 
Antiastharnatic
 
Antialtergic 
 
AstraZeneca, 
Wilmington, 
USA 
Amarin Corp., 
London, UK 
Bristol Myers 
Squibb, NY, 
USA 
Prographarm, 
Chateauneuf, 
France 
Panacea 
Biotech, New-
Delhi, India . 
Torrent 
Pharmaceuticals 
Ahmedabad, 
India 
Ranbaxy Labs 
Ltd., 
New-Delhi, 
India 
Ranbaxy Labs 
Ltd., 
New-Delhi, 
India 
Warner 
Lambert, 
NJ, USA 
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2.LITERATURE REVIEW 
 
Rajan et al.,14(2012) prepared the fast disintegrating tablets of Diclofenac sodium by direct 
compression method. Six formulation of different concentrations of superdisintegrants were 
prepared.In-vitro drug release studies were conducted two formulations with concentration 
of croscarmellose sodium and crospovidone showed excellent disintegrants property. 
 
Mayank P et al.,15(2011) prepared fast dissolving tablets of Lorazepam by direct 
compression method. Disintegration time and drug release was taken as the basis to optimize 
the rapidly disintegrating tablet. Prepared tablets were evaluated for post-compression 
parameters,in-vitro and dissolution drug release profile.  The formulated tablets had good 
appearance and better drug release properties as compared to marketed conventional tablets. 
Croscarmellose sodium in the concentration of 12% showed shorter disintegration time in 
33sec shows 95.99% drug release within 10min was selected as optimized formulation. 
 
Ganesh K.G et al.,16(2010) prepared the fast dissolving tablets of Chlorpromazine HCL by 
direct compression method using superdisintegrants, the fast dissolving tablet formulation 
showed enhanced drug release. 
 
Aravind K.S et al.,17(2010) prepared fast dissolving tablets of Salbutamol sulphate by direct 
compression method using super disintegrating agents like Ac-di-sol, poly plasdone, 
primojel, and MCC,mannitol were used as diluents. The formulations containing Ac-di-sol 
as superdisintegrating agent showed rapid disintegration time as compared to other 
formulations. 
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Sudhir B et al.,18(2010) formulated fast dissolving tablets of Aceclofenac by using super 
disintegrants like sodium starch glycolate. The tablets were evaluated for post-compression 
parameters, in- vitro dissolution studies. All formulations showed disintegration time in the 
range of 12.22 to 27.25 seconds along with rapid in-vitro dissolution. The fast dissolving 
tablets showed enhanced dissolution, taste masking and hence better patient compliance. 
 
Shishu et al.,19(2010) developed taste masked microsphere of ornidazole from eudragit E-
100 by solvent evaporation technique using sodium starch glycolate. 
 
Keng et al.,20(2010) developed Rizatriptan benzoate mouth dissolving tabletby using super 
disintegrating agents like crospovidone, Indion 414 and Indion 234 by direct compression 
method. 
 
N.G Nagendrarao et al.,21(2010) formulated metoprolo tartrate by sublimation methodby 
using super disintegrating agents like sodium starch glycolate, crospovidone, croscarmellose 
sodium, indion-414. 
 
Prabhu H et al.,22(2009) prepared Cinnarazine fast dissolving tablets by direct compression 
method by using natural superdisintegrants.The drug and polymer interaction were evaluated 
using FTIR. All polymers and excipients used were compatible with the drug.  It was found 
that results pre-compression parameters and post compression parameters were found to be 
satisfactory. The time taken for the in-vitro disintegration and in-vitro dispersion were found 
to be within limits. In-vitro drug release showed almost 90% of the drug was released from 
all formulations within 15min, thus crospovidone and treated agar proved to be best 
disintegrants. 
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Kawtikwar P.S et al.,23(2009) prepared fast dissolving tablets of Tizanidine Hydrochloride 
using superdisintegrants. They carried out disintegration time studies were found to be 
22sec. Tablets prepared by addition of superdisintegrants had less disintegration time than 
those prepared by sublimation method. 
 
Jain et al.,24(2009) developed fast dissolving tablets of valsartan using different 
superdisintegrants by direct compression method. Evaluated the prepared tablets for post-
compression parameters and in-vitro dissolution. Tablets were evaluated for disintegration 
time. Tablets containing crospovidone showed least wetting time and showed fast 
disintegration time. The drug release from fast dissolving tablets increased with increasing 
concentration of superdisintegrants. 
 
Anupama K et al.,25(2009) prepared mouth dissolving tablets of Oxcarbazepine by 
directcompression method using crospovidone as a superdisintegrant and aspartame as 
sweetener. Solid dispersions of oxcarbazepine with polyvinylpyrrolidine and polyethylene 
glycol 6000 were prepared. Solid dispersions with polyvinylpyrrolidone K-30 in 1:2 ratios of 
drug carrier showed maximum drug release and hence compressed with other excipients. 
Oxcarbazepine tablets prepared using solid dispersion technology was found to have good 
technological properties  and reproducible drug dissolution profiles. 
 
Nagendrakumar D et al.,26(2009) prepared fast dissolving tablet of fexofenadine HCL by 
effervescent method using crospovidone, croscarmellose sodium, sodium starch glycolate as 
super disintegrating agents. 
 
MallikarjunaSetty et al.,27(2008) designed the fast dispersible Aceclofenac tablet and the 
effect of functionality of super disintegrating agents by direct compression method. Effect of 
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super disintigrants such as croscarmellose sodium, sodium starch glycolate, crospovidone on 
wetting time, disintegration time, drug content, in-vitro release has been studied. 
Disintegration and dissolution parameter decreased with increased in level of disintegrates. 
 
T V Rao et al.,28(2008) worked on the cefadroxil dispersible tablets by direct compression 
technique using super disintegrating agents as crospovidone, croscarmellose sodium, sodium 
starch glycolate. The tablets were evaluated for hardness, friability, disintegration, 
dissolution time, wetting time and water absorption ratio. 
 
S. Shirsand et al.,29(2008) designed fast dissolving tablet of clonazepam by direct 
compression method using crospovidone, croscarmellose sodium and sodium starch 
glycolate, micro crystalline cellulose, mannitol. 
 
SajalkumarJha et al.,30(2008) developed melt in mouth dissolved tablet of Halopridol by 
direct compression method using super disintegrating agents like croscarmellose sodium, 
sodium starch glycolate, crospovidone. 
 
R. C. Doijad et al.,31(2008) formulated mouth dissolving tablet of Granisetron by wet 
granulation method using PVPk-32 and different super disintegrating agents like Avicel101. 
Almost 80% of the drugs were released from all formulations within 60sec. 
 
Aithal. K et al.,32(2006) developed once daily fast dissolving tablet of GranisetronHcl by 
direct compression method using super disintegrating agent formulation containing 
crospovidone and croscarmellose sodium shows shortest disintegrating time.  
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M.M. Patel et al.,33(2006) developed fast disintegrating valdecoxib tablet containing solid 
dispersion of voldecoxib with mannitol, PEG-4000 and poly vinyl pyrrolidine K-12. Poly 
vinyl pyrrolidine K-12 showed maximum drug release. 
 
Halakatti P.K et al.,34(2006) developed rapidly disintegrating tablet of domperidone by 
mass extrution technique and treated agar method by using sodium starch glycolate as super 
disintegrating agent. 
Sreenivas et al.,35(2006) developed the formulation and evaluation of ondansetron HCL fast 
dissolving tablet by using super disintegrating agent like sodium starch glycolate and 
crospovidone,  croscarmellose by direct compression method. 
 
I.S. Ahmed et.al., 36 (2006) designed fast dissolving Ketoprofen tablet using Freeze drying 
in blisters technique. The tablets were evaluated for saturation solubility and dissolution 
characteristics on comparison with the plain drug and physical mixture. Results showed 
increase in solubility and also 95% of Ketoprofen in fast dissolving tablet dissolved within 5 
minutes. 
 
Marzia cirri et.al.,37(2005) developed fast dissolving tablets of Flurbiprofen cyclodextrin 
system. Beta cyclo dextrin, methyl-beta-cyclodextrin and Hydroxy ethyl-beta-cyclo dextrin 
were evaluated. All formulations containing drug cyclodextrin systems gave a higher drug 
dissolved amount than the corresponding ones with drug alone. 
 
Devi V.K. et. al.,38(2006) developed Orodispersible Fluconazole tablets with two different 
volatilizable compounds like camphor and ammonium chloride by wet granulation method 
and the tablets were evaluated and the best formulations chosen were compared with 
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marketed conventional tablets. The formulated tablets exhibited instantaneous disintegration 
compared to marketed tablets. 
 
Halakatti P.K. et.al.,39(2006) developed Rapidly disintegrating tablets of Domperidone by 
mass extrusion technique and treated agar method. The time taken for in-vitro disintegration, 
in-vivo disintegration and in-vivo dispersion were found in the range of 8-20 sec, 11-25 sec 
and 17-32 sec. respectively. 
 
Shirwaikar A.et.al.,40(2006) developed once daily fast dissolving tablets of Granisetron-
HCL by Direct Compression method using superdisintegrants. Formulations containing 
Crospovidone and Croscarmellose Sodium shows shortest disintegration time. 
 
D.M. Patel et.al.,41(2006) developed fast dissolving Valdecoxib tablets containing solid 
dispersion of Valdecoxib with Mannitol, Polyethylene glycol-4000 and Polyvinyl 
pyrrolidone k-12. Valdecoxib solid dispersion with Polyvinyl pyrrolidone K-12 showed 
maximum drug release. 
 
Chaudhari P.D.et.al.,42(2005) formulated and evaluate fast dissolving tablets of 
Famotidine,which is bitter in taste and has low bioavailability (40-45%). Bitter taste of 
Famotidine was masked using Drug : Eudragit E100 in different ratios (1:1-1:10). The 
formulation containing 2% Ac-Di-Sol and Polyplasdone showed 91.89% and 101.07% 
release respectively in 12 minutes. 
 
Kaushik. D.et.al.,43(2004) formulated and evaluate Olanzapine mouth dissolving tablets by 
effervescent formulation approach sodium bicarbonate and citric acid were used as 
effervescent agents and their ratio in the formulation was optimized. The study revealed that 
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10:8 ratio of sodium bicarbonate and citric acid in the Olanzapine mouth dissolving tablets 
gave a soothing fizz, excellent mouth feel, good palatability and quick dissolution profile. 
 
Mishra. D.N.et.al.,44(2005) designed rapidly disintegrating oral tablets of Valdecoxib using 
various super disintegrants following Direct compression technique. All the formulations 
showed disintegration time of less than 60 seconds along with rapid in-vitro dissolution. 
 
A.A. Shirwaikar et.al.,45(2004) developed fast disintegrating tablets of Atenolol by Dry 
granulation method using three superdisintegrants like Ac-Di-Sol, Polyplasdone-XL & 
Explotab Ac-Di-Sol proved to be the best among the three and showed satisfactory results at 
3kg/cm2  hardness. 
 
Kuchekar B.S.et.al.,46(2004) designed mouth dissolving tablets of Salbutamol sulphate by 
factorial design technique using superdisintegrants like Sodium starch glycolate, 
Croscarmellose sodium and Treated agar, Microcrystalline cellulose as diluent. Formulations 
containing Sodium starch glycolate along with other super disingrants showed rapid in-vitro 
and in-vivo dispersion time. 
 
Nayak. S.M.et.al,47(2004) designed fast dissolving tablets for Promethazine theoclate using 
Effervescent melt, Superdisintegrant addition and Melt technologies. Tablets from 
Effervescent melt and Superdisintegrant addition technique released 92% and 89% of the 
drug at the end of 10 minutes. 
 
Mane Avinash. R.et.al.,48(2003) prepared mouth dissolving tablets of Domperidone using a 
meltable binder polyethylene glycol-4000, a diluent mannitol and a component which 
sublimes readily like camphor/ammonium carbonate. Two of the formulations having 40% 
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w/w of ammonium carbonate and 20%w/w of camphor were found to be exhibiting 
disintegrating time of 19.66 seconds and 21.33seconds. 
 
Amin. P.D.et. al.,49(2005) designed fast disintegrating dosage form of Ofloxacin and 
Metronidazole Benzoate using cationic exchange resins. Taste evaluation of the tablets 
showed complete masking of the bitterness of Ofloxacin. 
 
H.S. Mahajan et al., 50(2005) designed Rapidly disintegrating tablets of Piroxicam for 
elderly patients using super disintegrants like Sodium starch glycolate,cros carmellose 
sodium, low substituted propyl cellulose and microcrystalline cellulose [Avicel pH-102] was 
used as diluent. The tablets exhibited rapid disintegration and faster release rate of 
Piroxicam. 
 
Sreenivas S.A et.al.,51(2006) formulated and evaluate Ondansetron-HCL directly 
compressed mouth disintegrating tablets using disintegrants like crospovidone, 
croscarmellose sodium, pregelatinized starch, sodium starch glycolate and L-HPC were used 
along with other additives. Results suggests that a 10% disintegrant concentration is suitable 
for the preparation of ondansetron HCL mouth disintegrating tablets and the tablets 
containing crospovidone and croscarinellose, sodium are the best. 
 
Mishra. D.N.et.al.,52(2006) designed rapidly disintegrating oral tablets of Meloxicam using 
superdisintegrants like Ac-Di-So1, Sodium starch glycolate, low molecular weight hydroxy 
propyl methyl cellulose. The disintegration time in the oral cavity was also tested and was 
found to be around 1 minute. 
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S. Pandey et.al., 53(2003) designed to optimize fast dissolving dosage forms of Diclofenac 
sodium by rapidly disintegrating agents like Crosslinked carboxymethyl cellulose, Sodium 
starch glycolate and Croslinked povidone in different concentrations. Tablets containing 
Cross linked carboxy methyl cellulose showed better disintegrating character along with 
rapid release (90% drug release in 10 minute). 
 
B.S. Kuchekar et.al.,54(2004) designed mouth dissolve tablets of Diltiazem hydrochloride  
using disintegrants like Sodium starch glycolate, Carboxymethyl cellulose sodium and 
Treated agar by direct compression method. Almost 90% of drug were released from all 
formulations within 10 minutes. 
 
J.K. Lalla et.al.,55(2004) designed fast dissolving Rofecoxib tablets with cyclodextrin using 
Ball milling technique and evaluated using DSC. The fast dissolving tablet composition with 
25mg equivalent Rofecoxib showed complete release of Rofecoxib in 12 minutes as 
compared to 20% drug release from the conventional release marketed tablets during the 
same period. 
 
Rajanna S.G. et.al.,56(2006) designed and characterization of orodispersible Valdecoxib 
tablets using Mass extrusion technique and Sublimation method. The disintegration was 
achieved within 30 seconds from all the formulations prepared by both methods when 
observed in the saliva of healthy volunteers. The in-vitro dissolution was almost 90% within 
15 minutes for all formulations. 
 
Shishu et.al., 57(2005) Prepared and evaluate fast disintegrating oral dosage forms of 
Diazepam and Chlorpheniramine maleate using Microcrystalline cellulose as directly 
compressible filler binder and sodium starch glycolate as super disintegrant panel testing 
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data collected from 20 healthy volunteers indicate successful formulation of oral fast 
disintegrating tablets which had good taste and disintegrated in the oral cavity within 30 
seconds. 
 
Srinivasa Rao. M. et.al., 58(2005) designed orally disintegrating tablets of Nimesulide by 
direct compression method using crospovidone, cros carmellose sodium and sodium starch 
glycolate as super disintegrants. In all formulations cumulative % drug release increased 
with time and 99% of drug was released in 60 minutes. Croscarmellose sodium formulations 
showed faster drug release when compared to the Cros povidone and Sodium starch 
glycolate formulations.  
 
Vandana B. Patravale et.al., 59(2005) developed taste masked resonates of the Quinine 
sulphate drug using ion exchange resins. The taste masked complex was then formulated 
into a prototype suspension base and evaluated for various quality control parameters. Taste 
evaluation showed complete masking of the bitterness of the drug. In-vitro release studies 
revealed complete drug elution from the complex after a period of 30 min in pH-1.2 buffer. 
 
Mashru R.C. et.al., 60(2005) prepared and optimize the fast dissolving film of Salbutamol 
sulphate prepared using Solvent evaporation technique containing Polyvinylalcohol, 
Glycerol and Mannitol. Multiple regression analysis and polynomial regression analysis 
were carried out. The experimental results indicated that polymer concentration, plasticizer 
concentration and filler concentration had complex effects on film mechanical behaviour and 
% drug release. 
 
Mukesh. Gohel. et.al., 61(2004) designed to develop mouth dissolve tablets of Nimesulide. 
Granule containing Nimesulide, Camphor, Crospovidone and lactose were prepared by wet 
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granulation technique and the tablets were evaluated for percentage friability, wetting time 
and disintegration time. 32 full factorial designs was used to investigate the joint influence of 
2 formulation variables, amount of Camphor and Crospovidone. The results of multiple 
linear regression analysis revealed that for obtaining a rapidly disintegrating form tablets 
should be prepared using an optimium concentration of camphor and a higher percentage of 
Crospovidone. 
 
Kakasaheb R. Mahadik et.al., 62(2000) studied on New drug delivery systems for elderly 
with improved patient compliance and optimizing dosage regimen. Oral new drug delivery 
systems like jelly preparation, rapidly disintegrating oral tablets and fast dissolving dosage 
form are some of the examples of drug delivery systems specifically developed for geriatric 
patients. 
 
D.M. Patel et al., 63(2004) designed studies in formulation of orodispersible tablets of 
Rofecoxib using Sodium starch glycolate, Crospovidone and Croscarmellose sodium along 
with mannitol as diluent and the tablets were evaluated. 
 
Suresh Bandari et.al.,64(2006) studied on Development and evaluation of orally 
disintegrating tablets of Domperidone by direct compression technique employing three 
super disintegrants in 4,6 and 8% concentrations and evaluated for thickness, hardness, 
friability, assay, disintegration time, drug release studies, wetting time, water absorption 
ratio and disintegration in oral cavity. Drug release studies revealed that with increase in the 
concentration of superdisintegrant the cumulative % drug release increased with time and 
99% of drug was released in first five minutes in all the formulations. 
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Khushwant. S. Yadav et.al., 65(2006) designed and in-vitro and in-vivo evaluation of 
orodispersible tablets of Ondansetron-HCL with the aim to provide quick onset of action in 
the condition of emesis. The results suggest that the formulated tablet was a rapidly 
disintegrating tablet have an ease of administration along with increased bioavailability. 
 
Gandhi et.al., 66(2006) designed taste masking and development of a rapid disintegrating 
oral dosage form of Gatifloxacin-Sesquihydrate using Resin. The results suggested that the 
formulation of oral fast disintegrating tablets which had good taste and disintegrated in oral 
cavity within 21 seconds. 
 
Shirsand S.B. et.al., 67(2006) designed preparation of orodispersible tablets of Meloxicam 
by sublimation and effervescent methods with a view to enhance patient compliance 
formulation prepared by effervescent method emerged as the overall best formulation. 
 
Nagendra Kumar D. et.al., 68(2006) designed development of quick dissolve tablets of 
Tenoxicam by direct compression, sublimation and effervescent techniques and evaluted. 
Tablets prepared by effervescent method containing 12% w/w each of sodium bicarbonate 
and anhydrous citric acid were found to be promising. 
 
Arun Shirwaikar et.al., 69(2006) designed formulation and evaluation of fast dissolving 
tablets of Granisetron-Hcl by Direct compression method. The tablets prepared with smaller 
sized camphor particles were found to disintegrate faster than the tablets prepared with 
larger sized camphor particles. 
 
Marina Koland et.al., 70(2006) Studied on design of fast mouth dissolving tablets of 
Terbutaline sulphate and their characterization. The tablets were prepared using 3 different 
technologies viz. by Effervescent formulation approach with addition of citric acid and 
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sodium bicarbonate as effervescing agents, by the addition of superdisintegrants such as 
Sodium starch glycolate along with other disintegrants such as SCMC and PVP, by 
sublimation method using subliming agents such as camphor and ammonium carbonate in 
different ratios. FMDT of Terbutaline sulphate can be successfully formulated by 
sublimation method. 
 
S.L. Raut et.al., 71(2006) designed evaluation of Bamboo manna as super disintegrant in 
mouth dissolving tablet. Disintegration rate of Paracetamol formulation containing natural 
disintegrant Bamboo manna and Paracetamol formulation containing Sodium starch 
glycolate were compared for their pharmaceutical properties. Bamboo manna is proved to be 
economical disintegrant in formulation of mouth dissolving tablets with Sodium starch 
glycolate. 
 
Jain S.P. et.al., 72(2006) designed mouth dissolving tablets of Fexofenadine – HCL by taste 
masked drug resin complex by granulation technique using excipients like super 
disintegrants, sweeteners and lubricants. The results suggests that Fexofenadine HCL could 
be successfully taste masked by complexation. 
 
R. Senthil Prabhu, et. al.,73(2005) designed Fabrication and Characterization of Melt-in-
Mouth tablets of Valdecoxib to increase the bioavailability of the drug by Direct 
compression method using various superdisintegrants like Sodium starch glycolate, Cros 
carmellose sodium, Crospovidone, Polyvinyl pyrollidone and Beta cyclodextrin. Then the 
tablets were evaluated. In all batches of tablets Cumulative amount of drug release increased 
with time. 
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Amin P.D et al., 74(2005) designed disintegration dosage form of ofloxacin and 
metronidazole Benzoate using cationic exchange resins. Taste evaluation of the tablets 
showed complete masking of the bitterness of ofloxacin. 
 
Mishra D.N et al., 75(2005) designed rapidly disintegrating oral tablet of valdecoxib using 
various super disintegrating agents following direct compression technique. All the 
formulations showed disintegration time 60sec along with in-vitro dissolution rate. 
 
Anroop B, Nair et al., 76(2005) designed controlled release matrix uncoated tablets of 
enalapril maleate using HPMC. Two grades of  HPMC (K100 and K4 M) in different 
properties were used to prepare tablets by direct compression technique. 
 
Kaushik.D  et al., 77(2004) studied the fast dissolving tablets of olanzapine by effervescent 
formulation approach using different ratios of sodium bicarbonate and citric acid and 
reported 10:8 ratio of sodium bicarbonate and citric acid in the olanzapine MDT shows good 
palatability and quick dissolving profile. 
 
Kuchekar B et al., 78(2004) studied the formulation of salbutamol sulphate by direct 
compression using sodium starch glycolate, Crospovidone, treated agar as superdisintegrants 
and reported sodium starch glycolate exhibiting rapid dispersion than other 
superdisintegrant. 
 
Nayak S.M et al., 79(2004) studied the FDT of promethazine theoclate using effervescent 
melt, super disintegration addition and melt technologies. The effervescent melt and super 
disintegration addition techniques releases 92% and 89% of the drug at the end 10mins 
respectively. 
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Gohel M et al., 80(2004) designed mouth dissolving tablets of Nimesulide using vacuum 
drying technique. The sublimation of camphor from tablets by vacuum drying results faster 
disintegration. 
 
Chandrashekar .N.S et al.,81(2004) studied the fast dissolving tablets containing novel gas-
evolving disintegrant. The relative efficiency of improvement was in the range of 
Crospovidone> ac-di-sol >primojel. 
 
Kasture V.S33 et al., 82(2004) studied the Spectrometric method for simultanesous 
estimation of oflaxacin and ornidazole in tablet dosage form. 
 
A.A. Shirwaiker et al., 83(2004) developed disintegrating tablet of atenolol by dry 
granulation method using three super disintegrates like AC-Di-Sol proved to be the best 
among the three and showed satisfactory results at 3kg/cm3 hardness. 
 
J.K. Lalla et al., 84(2004) designed fast disintegrating Rofecoxib tablet with β- cyclodextrin 
using ball milling technique and evaluated using DSC. The fast disintegrating tablet 
composition with 25mg equivalent Rofecoxib in 12min is compared to 20% drug release 
from the conventional release marketed tablet during the same period. 
 
H.S. Mahajon et al., 85(2004) designed mouth dissolving tablet of sumatriptan succinate 
using disintegrating agents like sodium starch glycolate, carboxy methyl cellulose sodium, 
and treated sugar by direct compression method. Almost 90% of the drugs were released 
from all formulations within 10 mins. 
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Shenoy .V et al., 86(2003) studied the fast dissolving tablets diclofenac sodium using direct 
compression after incorporating rapid disintegrants such as sodium starch glycolate, 
Crospovidone, croscarmellose sodium. Croscarmellose sodium is better for the formulation 
of FDT of diclofenac sodium. 
 
Robinson Joseph et al., 87(2003) reported the effervescent granulations of narcotics, 
antibacterial agents , antiviral agents, anxiolytic agents, a cholesterol lowering agent, an 
alpha adrenergic blocking agent and synthetic antibacterial agents and the preparation of 
MDT from effervescent granules. 
 
Andaleeb Ahmed et al., 88(2003) described the key ingredients used in the formulation of 
fast dissolving tablets and about the technologies used in preparations. 
 
Chandrasekhar et al., 89(2003) studied the analysation of mouth dissolving tablets using 
revolution technology with E-tongue apparatus. 
 
B.P. Panda et al., 90(2003) studied nimesulide mouth fast dissolving effervescent tablets. 
Formulation containing 15% of the effervescent ingredients divided as internal disintegrants 
and external disintegrants in the ratio of 2:1 is the best acceptable fast dissolving dosage 
form. 
 
 Poornima D et al., 91(2002) studied the fast dissolving tablets of taste masked complex of 
roxithromycin. The taste masking of roxithromycinviz granulation with eudragit E100 and 
complexation with ion exchange resin and compressing with superdisintegrant.  
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Schiermeiers S,et. al., 92(2002) studied the formulation of ibuprofen fast dissolving tablets 
by direct compression method. 
 
Sheetalmalke et al., 93(2002) formulated oxcarbazepine fast dissolving tablet by using 
Avicel PH 102 as a diluents and Ac- di – sol as a super disintegrating agent by wet 
granulation method. 
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3.1 AIM OF THE WORK 
 
 The aim of the proposed work was to formulate and characterize Oro dispersible 
tablets (ODT) of Diltiazem Hydrochloride for rapid dissolution of drug and absorption, which 
may produce rapid onset of action in the management of hypertension in elderly patients. 
ODT of Diltiazem hydrochloride which when placed in the tongue disintegrates or 
dissolves rapidly in the saliva without the need of drinking water. 
 
As tablet disintegrates in the mouth, this could enhance the clinical effect of the drug 
through Pregastric absorption from the mouth, pharynx and oesophagus. This leads to an 
increase in bioavailability by avoiding first pass liver metabolism. Diltiazem hydrochloride is 
a new generation calcium channel blocker with peripheral and coronary vasodilator 
properties, which is used in the management of classical, and vasospastic angina pectoris and 
also in the treatment of essential hypertension. The plasma half-life following a single oral 
dose is 3-4 hrs. The success of a therapy depends on selection of the appropriate delivery 
system as much as it depends on the drug itself. Thus diltiazem hydrochloride is chosen as a 
suitable candidate for Oro dispersible tablets drug delivery system. 
 
Hence ODT of Diltiazem hydrochloride  has been developed with the goal of 
speeding absorption and onset of effect compared to standard Diltiazem hydrochloride  
tablets with the following objectives. 
 
 To provide convenient dosing 
 To achieve rapid dissolution rate for the drug. 
 To improve the bioavailability of the drug. 
 To facilitate faster onset of therapeutic action. 
 To make easier administration for geriatrics, mentally ill patients and dysphagia 
patients. 
                                .  
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3.2 PLAN OF THE WORK 
 
Present work was carried out to design and evaluate the Oro dispersible 
tablets.  
The study was proposed to carry out in the following stages.  
 
 Preformulation studies 
 Construction of standard curve for  Diltiazem hydrochloride. 
 Fabrication of Oro dispersible tablets of Diltiazem hydrochloride . 
 Evaluation of Oro dispersible tablets 
 Comparative in-vitro drug release studies with Marketed samples of the same 
drug. 
 In-vitro drug release studies. 
 Stability studies 
 Investigation of drug release kinetics 
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3.3 SCHEME FOR MECHANISM  ORO DISPERSIBLE TABLET.  
 
 
Oro dispersible tablets 
 
↓ 
 
Placed in tongue 
 
↓ 
 
Instantaneous Disintegration in mouth 
 
↓ 
 
Rapid drug dispersion/ dissolution in saliva 
 
↓ 
 
Pre-gastric absorption 
 
↓ 
 
Avoids frist pass metabolism 
 
↓ 
 
Increase in Bio availability 
 
↓ 
 
Faster onset of action 
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4. METHOD  
 
4.1 MATERIALS USED 
Sl. No. Materials Suppliers 
1.        Diltiazem hydrochloride      
Nicholas Piramal India 
Ltd 
2. Crospovidone (Polyplasdone XL) Micro labs, Hosur 
3. Croscarmellose Sodium (Ac-Di-Sol) Signet chemical corporation, Mumbai 
4. Sodium starch glycolate (Glycolys) Signet chemical corporation, Mumbai 
5. Colloidal silicon dioxide (Aerosil) Micro labs, Hosur 
6. Mannitol-DC Micro labs, Hosur 
7. Micro crystalline cellulose powder  (Avicel PH-102) 
S.D. Fine chemicals, 
Boisar 
 
8. Saccharin Sodium S.D. Fine chemicals, Boisar 
9. Magnesium stearate S.D. Fine chemicals, Boisar 
10. Potassium dihydrogen Phosphate (AR) 
S.D. Fine chemicals, 
Boisar 
11. Sodium hydroxide (AR) S.D Fine chemicals, Boisar 
 
Table: 4 MATERIALS USED 
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4.1.2 INSTRUMENTS USED 
 
S.No Instruments Suppliers 
1 Single pan electronic balance Shimadzu corporation, Japan 
2. pH meter Elico 
3. Single Beam UV-visible Spectrophotometer 
1201,Shimadzu corporation, 
Japan 
4. FTIR spectrophotometer Perkin. Elmer, Germany 
5. Dissolution apparatus Disso 2000, Lab India, Chennai 
6. Disintegration tester Electrolab, Chennai 
7. Friability test apparatus Roche Friabilator 
8. Vernier calipers Mitutoyo Corps, Japan 
9. Hardness Tester Monsanto 
10. 16 station Rotary Tablet compression machine  Cadmach, India 
11. Sieves Goston, India 
12. Stability chamber Osworld, Mumbai 
 
 Table: 5  INSTRUMENTS USED 
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4.2 DRUG PROFILE 
DILTIAZEM HYDROCHLORIDE94 
 
Drug Name: Diltiazem hydrochloride 
Structure:  
S
N
O
H
OOCH3
OCH3
H
(H3C)2NH2CH2C  
 
Molecular formula: C22H26N2O4S.HCL 
Molecular Weight: 414.52 
Category: Antianginal, Calcium channel blocker 
Description:  
White crystalline powder / small crystals 
 
Solubility:  
Freely soluble in water, methanol, chloroform and formaldehyde. Insoluble in 
benzene. 
Melting Point:  
Melts at above 210oC with decomposition 
 
Standards: Diltiazem is (+) is C 2,3,4,5 tetra hydro -5- (2 dimethyl amino ethyl) -2- (-4 
methoxy phenyl) 4-oxobenzene (6) thiazepin-3yl acetate monohydrochloride. It contains not 
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less than 98.3% and not more than 101.9% C22H21N2O4S2HCl calculated with reference to 
dried substance. 
 
Therapeutic uses 
Variant angina: 
Variant angina is as a result of reduction in blood flow. The drug can attenuate 
ergonovine-induced vasospasm in patient with variant angina 
 Exertional angina:  
Effective in the treatment of exertional or exercise induced angina. The utility of this 
agent results in an increase in blood flow due to coronary arterial dilation. 
Unstable angina:  
It is a recurrent angina, associated with minimal exertion. It is prolonged and frequent. 
Coronary flow is severely restricted and it is likely that vasospasm also occurs in some 
patients. 
 
Other uses: Antiarrythmic 
 
Dose: 
 Given orally (30mg) 4 times daily, usual dose in 60 mg three times daily. Sustained 
release preparation is given twice daily. 
 
Pharmacokinetics 
 Diltiazem is rapidly and almost completely absorbed from the gastrointestinal tract 
following oral administration, but undergoes extensive first pass hepatic metabolism. The 
bioavailability has been reported to be about 40%, although there is considerable inter-
individual variation in plasma concentrations. 
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 Diltiazem is around 50% bound to plasma protein. It is extensively metabolized in the 
liver, one of the metabolites desacetyl diltiazem has been reported to have 25 to 50% of the 
activity of the parent compound. The plasma half-life is 3-4 hours. Approximately 60% of the 
dose is excreted in the bile and 35-40% in the urine, 2-4% as unchanged diltiazem. 
Adverse effects 
1. Depression of cardiac conduction, atrioventricular block 
2. Headache, dizziness, ankle oedema, flushing, hypotension, nausea and gastrointestinal 
discomfort. 
3. There have been reports of hyperactivity sometimes with associated psychiatric 
symptoms. Gynaecomastia has also been reported. 
 
Precautions 
1. Diltiazem should be administered with caution to patients with pre-existing 
hypertension and probably along to those with impaired left ventricular function due 
to the potential negative ionotropic properties of diltiazem. 
2. Treatment should commence with reduced doses in elderly patients and with impaired 
liver or kidney function. 
3. Diltiazem should be used in pregnant women only if the potential benefit justifies the 
potential risk to the foetus. 
 
Indication 
 Chronic stable angina, unstable angina, variant angina 
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Contraindication 
 Sick sinus syndrome, 2nd or 3rd degree AV block hypotension (systolic pressure < 
90Mm Hg) 
 
Commercially available dosage form 
Angizem (Sunpharma) : 30mg and 60mg 
Dilgard (Cipla)  : 30mg 
Dilzem (Torrent)  : 30mg and 60mg 
 
Sustained release dosage forms 
Angizem CD (Sun pharma)   : 90mg and 120mg 
Dilcontin XL (Modi Mundi Pharma) : 90mg and 180mg 
Dilzem SR (Torrent)   : 90mg 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS	AND	INSTRUMENTS																					
 
 
 
DEPARTMENT	OF	PHARMACEUTICS,	K.M.C.P.	MADURAI	 																																																				Page	48	
  
4.3 EXCIPIENTS LITERATURE 95 
 
4.3.1 CROSPOVIDONE 
Synonyms: 
 Crosslinked povidone; polyplasdone XL, Polyplasdone XL-10. 
Chemical Name: 
1- Ethenyl-2-Pyrrolidinone homopolymer 
 
Functional Category: 
 Tablet disintegrant 
 
Description: 
 Crospovidone is a white to creamy white, finely divided, free flowing, practically 
tasteless, odorless or nearly odorless, hygroscopic powder. 
 
Typical Properties: 
Density : 1.22 g/cm3 
Solubility : Practically insoluble in water and most common organic solvents 
Stability and Storage Conditions: 
 Crospovidone is hygroscopic. So it should be stored in an airtight container in a cool, 
dry place. 
 
Safety: 
 Crospovidone is used in oral pharmaceutical formulations and is generally regarded as 
nontoxic and non-irritant material. 
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Applications: 
 Crospovidone is a water insoluble tablet disintegrant and dissolution agent used at 2-
5% concentration in tablets prepared by direct compression. 
 Cros povidone can be used to enhance the solubility of poorly soluble drugs in co-
evaporation technique. 
 
4.3.2 CROSCARMELLOSE SODIUM 
Synonyms: 
Ac-Di-Sol, Crosslinked carboxymethyl cellulose-sodium, modified cellulose gum, 
primellose, solutab. 
 
Chemical Name: 
Cellulose, Carboxy methyl ether, sodium salt, Crosslinked. 
 
Functional Category: 
 Tablet and capsule disintegrant. 
 
Description: 
 Croscarmellose sodium occurs as an odorless, white, colored powder. 
 
Typical Properties: 
 Density (bulk) : 048 g/cm3 
 Density (tapped) : 0.67 g/cm3 
            Solubility: 
   Insoluble in water, although Cros carmellose sodium rapidly swells to 4-8 times its 
original volume on contact with water. 
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Stability and Storage Conditions: 
 Cros carmellose sodium is a stable though hygroscopic material. A model tablet 
formulation prepared by direct compression with cros carmellose sodium as a disintegrant 
showed no significant difference in drug dissolution after storage at 30oC for 14 months. Cros 
carmellose sodium should be stored in a well closed container in a cool, dry place. 
 
Safety: 
 It is regarded as an essentially non-toxic and non-irritant material. However oral 
consumption of large amounts of Cros carmellose sodium may have a laxative effect 
although the quantities used in solid dosage formulations are unlikely to cause such problems. 
 
Applications: 
 Cros carmellose sodium is used in oral pharmaceutical formulations as a disintegrant 
for capsules, tablets and granules. In tablet formulations, cros carmellose sodium may be used 
in both direct compression and wet granulation process. Concentrations of upto 5% w/w of 
cros carmellose sodium may be used as a tablet disintegrant although normally 2% w/w is 
used in tablets prepared by direct compression. 
 
4.3.3 SODIUM STARCH GLYCOLATE 
Synonyms: 
 Carboxy methyl starch, Sodium salt, Explotab, Primojel. 
 
Chemical Name: 
 Sodium carboxymethyl starch 
 
Functional Category: 
 Tablet and capsule disintegrant 
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Description: 
 It is a white to off-white, odorless, tasteless, free flowing powder. It consits of oval or 
spherical granules, 30-100 m in diameter with some less spherical granules ranging from 1-
35  in diameter. 
 
Typical Properties: 
 Aciditiy / Alkalinity : pH = 3.0 – 5.0% 
 Density (Bulk) : 0.85 g/cm3 for primojel. 
           Melting Point:Does not melt, but chars at approximately 200oC 
             Solubility: 
 Sparingly soluble in ethanol (95%) practically insoluble in water at a concentration of 
2% w/v, it disperses in cold water and settles in the form of a highly hydrated layer. 
 
Stability and Storage Conditions: 
 Tablets prepared with sodium starch glycolate have good storage properties sodium 
starch glycolate is stable and should be stored in a well closed container to protect it from 
wide variations in humidity and temperature that may cause caking. 
 
Incompatibilities: 
 It is incompatible with ascorbic acid. 
Safety: 
 It is widely used in oral pharmaceutical formulation and is generally regarded as a 
non-toxic and non-irritant material. However oral ingestion of large quantities may be 
harmful. 
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Applications: 
 It is widely used in oral pharmaceuticals as a disintegrant in capsule and tablet 
formulation. It is commonly used in tablets prepared by either direct compression or wet 
granulation processes. The usual concentration employed in a formulation is between 2-8%, 
with the optimum concentration about 4%, although in many cases 2% is sufficient. 
Disintegration occurs by rapid uptake of water followed by rapid and enormous swelling. It  
has also been investigated for use as a suspending vehicle. 
 
4.3.4 MICROCRYSTALLINE CELLULOSE 
Synonyms: 
 Avicel, Emcocel and Tabulose 
 
Functional Category: 
 Adsorbent, suspending agent, tablet and capsule diluent, disintegrant 
 
Description: 
White coloured, odourless, tasteless, crystalline powder composed of porous particles. 
 
Typical properties: 
Solubility: 
 It is insoluble in water, slightly soluble in 5% w/v sodium hydroxide solution 
pH = 5.0 – 7.0 
Melting point : Chars at 260 – 270oC 
Moisture Content: 
 It is hygroscopic in nature, moisture content is less than 5% w/w. 
Density (Bulk): 0.337 g/cm3 
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Density (Tapped):0.478 g/cm3 
Stability and Storage Conditions: 
 Should be stored in well – closed container and kept in a cool and dry place. 
 
Incompatibilities: 
Incompatible with strong oxidizing agents 
 
Safety: 
 It is widely used in oral pharmaceutical formulations and food products and is 
generally regarded as non-toxic and non-irritant material 
 
Applications 
 It is widely used as a diluent in oral tablets and capsules.  It is used in both wet 
granutation and direct compression process.It is also used as tablet disintegrant. 
 
4.3.5 COLLOIDAL SILICON DIOXIDE 
Synonyms: 
 Aerosil, cab-o-sil, colloidal silica, fumed silica 
 
Description: 
It is submicroscopic fumed silica with a particle size of about 15nm.  It is a light, 
loose, bluish-white coloured, odorless, tasteless, nongritty amorphous powder. 
 
Functional Category: 
 Adsorbent, anticaking agents, glidant, suspending agent, tablet disintegrant, viscosity 
increasing agent 
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Typical properties: 
Solubility: 
 It is insoluble in water, organic solvents, and acids, except hydrofluoric acid.  It is 
soluble in hot solution of alkali hydroxide. 
Density (Bulk): 0.029 – 0.042 g/cm3 
Density (Tapped): 0.050 g/cm3 
 
Stability and Storage Conditions: 
 It is hygroscopic and absorbs large quantities of water without liquefying.so it should 
be stored in well-closed container in a cool, dry place. 
 
Incompatibilities: 
 Incompatible with diethyl stilbosterol preparations. 
Safety: 
 It is widely used in oral and topical pharmaceutical formulations and is generally 
regarded as a non-toxic and non-irritant material.  Intraperitoneal and subcutaneous injection 
may produce local tissue reactions and / or granulomas. 
 
Applications: 
 It is widely used in Pharmaceuticals, cosmetics and food products.  It is mainly used 
as a glidant for tabletting form, also used to stabilize emulsion and as a thixotropic thickening 
and suspending agent in gels and semisolid preparations.  It is also used as tablet disintegrant. 
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4.3.6 MANNITOL 
Synonyms: 
Cordycepic acid; E421; 1,2,3,4,5,6 – hexanehexol; manita; manna sugar; mannite; 
pearlitol. 
Chemical Name :D-Mannitol 
 
Functional Category: 
 Sweetening agent, tablet and capsule disintegrant, tonicity agent, vehicle for 
lyophilized preparations. 
 
Description: 
 It is a white, odorless, crystalline powder or free flowing granules.  It has a sweet 
taste. 
 
Solubility: 
 It is soluble in alkalis at 20oC, 1 in 5.5 parts is soluble in water at 20oC. 
 
Stability and Storage Conditions: 
 It is stable in the dry state and in aqueous solutions.  The bulk material must be stored 
in well closed containers in a cool, dry place. 
 
Incompatibilities: 
 It is incompatible with xylitol infusion and forms complexes with some metals (Fe, 
Al, Cu). 
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Safety: 
 Mannitol when consumed orally in large quantities laxative effects may occur.  An 
acceptable daily intake of mannitol has not been specified by the WHO since the amount 
consumed as a sweetening agent was not considered to represent a hazard to health. 
 
Applications: Mannitol is widely used in pharmaceutical formulations as a diluent (10 – 
90 % w/v) in tablet formulations,Where it is of particular value since it is not hygroscopic 
and may thus be used with moisture sensitive active ingredients. 
 
 Mannitol may be used in direct compression tablet applications.  Mannitol is 
commonly used as an excipient in the manufacture of chewable tablet formulations because 
of its negative heat of solution, sweetness and mouth feel. 
 
4.3.7 MAGNESIUM STEARATE 
Synonyms: 
 Stearic acid magnesium salt, magnesium salt, magnesium octadecanoate 
 
Description: 
It is a fine, white, precipitated or milled, impalpable powder of low bulk density, 
having a faint odor of stearic acid and a characteristic taste. 
 
Functional Category: 
Tablet and capsule lubricant 
Typical properties: 
    Solubility: 
 It is insoluble in water, ethanol and ether, slightly soluble in warm benzene and warm 
ethanol. 
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Melting point  : 117 – 150oc 
Density (tapped): 0.286 g/cm3 
Density (bulk) : 0.159 g/cm3 
 
Stability and Storage Conditions: 
 It should be stored in a well – closed container in a cool, dry place. It is a stable 
compound. 
 
Incompatibilities: 
 Imcompatible with strong oxidizing agents, strong acids, alkalis and iron salts.  It 
cannot be used in products containing aspirin, some vitamins and most alkaloidal salts. 
 
Safety: 
 It is widely used in pharmaceutical formulations and is generally regarded as a non-
toxic material.  However oral consumption of large quantity may result in some laxative 
effect or mucosal irritation. 
 
Applications: 
 It is widely used in cosmetics, food and pharmaceutical formulations.  It is  primarily 
used as  a lubricant in capsule and tablet at concentration between 0.25 – 5.0%. 
4.3.8 SACCHARIN SODIUM 
Synonyms: 
 1,2-Benzisothiazoline- 3- one 1,1-dioxide, sodium salt, Britsol, Crystallose, Degutan; 
E954, Kristallose, sodium-o-benzosulfimide, soluble gluside, soluble saccharin, sucaryl, 
sucromat; syncal s. 
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Chemical Name: 
 1,2 –Benzisothiazol-3 (2H)-one 1,1-dioxide sodium salt. 
 
Functional Category: 
 Sweetening agent 
 
Description: 
 It occurs as a white, odorless or faintly aromatic, efflorescent, crystalline power.  It 
has an intensely sweet taste. 
Typical properties: 
Melting Point: Decomposes upon heating 
Solubility: 
 It is soluble in pH 7.0 buffer at 1 in 1.21 at 25oC soluble in water at 1 in 1.2 at 25oC. 
 
Stability and Storage Conditions: 
It is stable under the normal range of conditions employed in formulations.  It should 
be stored in a well-closed container in a cool,dry, place. 
Safety: 
It is regarded as a safe intense sweetener.  The WHO has set a temporary daily intake 
of upto 2.5 mg / kg body weight for saccharin, including its salts. 
 
Applications: 
 It is an intense  sweetening agent used in beverages, food products, table top 
sweeteners and pharmaceutical formulations such as tablets,Powders, medicated 
confectionery, gels, suspensions and liquids. 
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Sweetening power is approximately 300 times  that of sucrose.  Saccharin  sodium 
enhances flavor systems and may  be used to mask some unpleasant taste characteristics. 
 
 
 
 
 
 
RESEARCH 
ENVISAGED 
 
 
 
RESEARCH	ENVISAGED	
	 																				
DEPARTMENT	OF	PHARMACEUTICS,	K.M.C.P.	MADURAI	 																																																												60	
	
 
5. EXPERIMENTAL INVESTIGATION 
 
5.1 CONSTRUCTION OF STANDARD CURVE OF DILTIAZEM 
HYDROCHLORIDE BY UV-SPECTROSCOPY METHOD 
 
Method of preparation of Sorenson’s buffer pH 6.8 96 
1. Preparation of 0.2 M Potassium dihydrogen phosphate solution (Primary 
solution): 
27.218 grams of Potassium dihydrogen phosphate was weighed and dissovled 
in small quantity of distilled water and the volume was made upto one litre with 
distilled water. 
2. Preparation of 0.2 M Sodium hydroxide solution (secondary solution): 
8 grams of sodium hydroxide was weighed and dissolved in distilled water and 
made upto one litre with distilled water. 
From the primary solution 50ml and from the secondary solution 22.4ml was taken and made 
upto 200ml with distilled water to get sorenson’s buffer and the pH was checked and adjusted 
to 6.8. 
 
Procedure for Construction of Standard Curve97 
Primary stock solution 
100mg of diltiazem hydrochloride was accurately weighed and dissolved in buffer pH 6.8 and 
then made up to 100ml a concentration of 1000 mcg/ml. 
Secondary stock solution 
1 ml of the primary stock solution was diluted with buffer pH 6.8 to get a concentration of 10 
mcg/ml. 
Sample solution 
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From the secondary stock solution aliquots ranging from 1ml to 10ml were pipetted out and 
diluted to 10ml with buffer to get the concentration of 1mcg/ml to 10mcg/ml. The absorbance 
was measured at 237 nm against blank. 
Then a caliberation curve was plotted taking concentration on X-axis and absorbance on Y – 
axis. 
 
Table:6. Standard Curve for Diltiazem hydrochloride using by 
using UV-Spectroscopy  Method 
 
Sl.No. Concentration (g/ml) Absorbance 
1 1 0.061 
2 2 0.121 
3 3 0.159 
4 4 0.225 
5 5 0.283 
6 6 0.335 
7 7 0.401 
8 8 0.458 
9 9 0.523 
10 10 0.571 
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Fig.5: Standard Curve For Diltiazem Hydrochloride by UV-Method 
5.2 PRE FORMULATION STUDIES98,99 
Preformulation testing is an investigation of physical and chemical properties of drug 
substances alone and when combined with excipients. It is the first step in the rational 
development of dosage form. 
 
1. Drug – Excipients compatibility studies  
About 50mg of Diltiazem hydrochloride  with various excipients in 1 : 1 ratio in glass 
vials were taken and kept at various accelerated condition (30oC / 65% RH, 40oC / 75% RH 
and 60oC / 80% RH) in stability chamber [osworld stability chamber, India] It is carried out 
for one month in open and closed glass vials. Samples were withdrawn at the intervals of 
1,2,3,4,5,6,7,14,21 and 30 days and physical characteristics like colour change if any was 
recorded. Finally the mixtures with no colour change were selected for Formulation 
development. 
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2. Angle of Repose ( ) 
It is defined as the maximum angle that can be obtained between the free standing of a 
powder heap and the horizontal plane which is given by the equation 
  = tan-1 


r
h  
  - Angle of repose 
h – Height of the pile 
r – Radius of the base of the conical pile 
3. Loss on Drying 
It was done in Electronic loss on Drying [LOD] apparatus [Sartorius, Germany]. 
Weighed quantity of 1 gram of sample was placed in the pan and the temperature was 
increased up to 500oC and the loss on drying in percentage was noted. 
4. Bulk Density, Tapped Density, Hausner Ratio and Carr’s Index  
Weighed quantity of powder blend was taken in a graduated cylinder and the bulk 
volume (Vb) was measured, and weight of the blend (M) was determined. The measuring 
cylinder containing known mass of powder blend was tapped for a fixed time and the tapped 
volume (Vt) occupied in the cylinder and the weight of the blend (M) was measured. From 
that bulk density, tapped density, Hausner bulk ratio and carr’s index were calculated. 
Bulk density (eb) = 
bV
M  
Tapped density (et) = 
tV
M  
Hausner ratio = 
b
t
e
e  
RESEARCH	ENVISAGED	
	 																				
DEPARTMENT	OF	PHARMACEUTICS,	K.M.C.P.	MADURAI	 																																																												64	
	
 
Carr’s index  (I) = 100x
e
ee
t
tb   
 
5. Infrared Spectroscopic Studies  
Identification of the pure drug and super disintegrants were performed using Infrared 
spectroscopy. 
Pressed Pellet Technique 
Sample and potassium bromide in the ratio of 1 : 100 were placed in a clean agate 
mortar and triturated well and the powder mixture is compressed in a mini press to get 
pellets. The pellet is placed in the sampling area of FTIR spectrophotometer and peaks 
obtained were identified. 
 
5.3 FABRICATION OF ORO DISPERSIBLE TABLETS OF DILTIAZEM 
HYDROCHLORIDE 
Direct Compression Method 
In this formulation of ODT of Diltiazem hydrochloride, Each superdisintegrant was 
employed in three concentrations (5,10 and 15%). The composition of ODT of Diltiazem 
hydrochloride was shown in Table: 1. weighed quantities of along with appropriate 
concentrations of superdisintegrant, mannitol-D, microcrystalline cellulose, colloidal silicon 
dioxide, saccharin sodium were weighed and mixed in geometric progression in a dry and 
clean mortar. Then the blend was passed through sieve No : 60. Then magnesium stearate 
was added and mixed well. 
 
The dry blend was compressed into tablets using 8 mm punches  in a 16 Station 
Rotary Tablet Machine [Cadmach, India]. Then the Fabricated tablets were evaluated for 
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thickness, diameter, hardness, friability, wetting time, water adsorption ratio, weight variation 
test, drug content uniformity, uniformity of dispersion, In- vitro dispersion time, In- vitro 
disintegration time, In-vitro dissolution studies, Moisture uptake studies, and Stability 
studies. 
 
 
 
 
 
EXPERIMENTAL  
INVESTIGATIONS 
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TABLE : 7.    COMPOSITION OF ORO DISPERSIBLE TABLETS 
(ODT’S) OF DILTIAZEM HYDROCHLORIDE 
 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 
Diltiazem 
Hydrochloride 
30 30 30 30 30 30 30 30 30 
SSG 
5% 10% 15% - - - - - - 
CCS - - - 5% 10% 15% - - - 
CP - - - - - - 5% 10% 15% 
MCC (mg) q.s q.s q.s q.s q.s q.s q.s q.s q.s 
Mannitol 15 15 15 15 15 15 15 15 15 
Aerosil 3 3 3 3 3 3 3 3 3 
Saccharin 
sodium 
2 2 2 2 2 2 2 2 2 
Magnesium 
stearate 
 
2 2 2 2 2 2 2 2 2 
 
 5.4  EVALUATION OF ORO DISPERSIBLE TABLETS (ODT’s)100-102 
(a) Thickness and Diameter 
The thickness and diameter of the tablets were carried out using vernier 
calipers (Mitutoyo corps, Japan). Five tablets were used for the above tests from 
each batch and results were expressed in millimeters. 
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(b) Hardness Test 63, 64 
Tablets require a certain amount of strength or hardness and resistance to 
Friability to with stand mechanical shocks of handling in manufacture, packing 
and shipping. The hardness of tablet was measured by Monsanto hardness tester, 
five tablets from each batch were used for hardness studies and results were 
expressed in Kg/cm2. 
(c) Weight variation Test 
Twenty tablets were selected at random, individually weighed in a single 
pan electronic balance [Ax, Shimadzu – corporation, Japan] and the average 
weight was calculated. The uniformity of weight was determined according to I.P. 
Specification. As per I.P. not more than two of individual weights would deviate 
from average weight by more than 5% and none deviates by more than twice that 
percentage. 
(d) Friability Test 
The friability of the tablet was determined using Roche friabilator. It is 
expressed in percentage (%). 20 tablets were initially weighed (Winitial) and 
transferred in to the Friabilator. The Friabilator was operated at 25 rpm for 4 
minutes. The tablets are weighed again (Wfinal). The % Friability was then 
calculated by 
F  = 100x
W
WW
initial
finalinitial   
F  % Friability 
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(e) Wetting Time  
Wetting time is closely related to the inner structure of tablets and to the 
hydrophilicity of the excipients. 
A linear relationship exists between wetting time and disintegration time. 
Thus wetting time is an important step for disintegration process to take place. 
Method : 
A piece of tissue paper folded twice was placed in a small Petridish 
(internal diameter = 6.5cm) containing 6ml of water. A tablet was placed on the 
paper and the time for complete wetting of the tablet was measured in seconds. 
Three trials for each batch were performed and standard deviation was also 
determined.  
(f) Water Absorption ratio  
A piece of tissue paper folded twice was placed in a small Petridish 
(internal diameter = 6.5cm) containing 6ml of water. A tablet was placed on the 
paper and time required for complete wetting was measured. The wetted tablet 
was then weighed. Water absorption ratio (R) was determined using following 
equation 
R = 100 x 
b
ba
W
WW   
Wa   weight of tablet after water absorption 
Wb  weight of tablet before water absorption 
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(g) Uniformity of dispersion test  
Two tablets from each batch were seperately kept in 100ml water and 
gently stirred for 2 minutes. The dispersion was passed through 22mesh. The 
tablets were considered to pass the test if no residue remained on the screen. 
 
(h) Drug Content uniformity test  
Powder equivalent to 50mg of Diltiazem hydrochloride was dissolved in 
sorenson’s buffer pH 6.8, sufficient dilutions were made. Absorbance of the 
resulting solution was measured at 237 nm using Shimadzu [UV-1201] 
spectrophotometer. From the absorbance values, amount of drug present in the 
given tablet was calculated. Procedure was repeated by using four more tablets 
from the same formulation and the average value of all five tablets were 
calculated. 
(i) Moisture Uptake Test  
Ten tablets from each formulation were kept in desiccators, over calcium-
chloride at 37oC for 24 hours. The tablets were then weighed and exposed to 75% 
RH, at room temperature for two weeks. Required humidity was achieved by 
keeping saturated sodium chloride solution at the bottom of the desiccator for 
three days. One tablet as a control (without superdisintegrants) was kept to assess 
the moisture uptake due to other excipients. Tablets were weighed and the 
percentage increase in weight was recorded. 
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(j) IN – VITRO DRUG RELEASE STUDIES 
(I) In- Vitro Dispersion Time  
In-vitro dispersion time was measured by dropping a tablet in a measuring 
cylinder containing 6ml of pH 6.8 (simulated saliva fluid). The time for the tablet 
to completely disintegrate into fine particles was noted. Three tablets from each 
batch were randomly selected and in-vitro dispersion time was performed. 
 
(II) In – Vitro Disintegration Time  
The disintegration time of the tablets was determined as per Indian 
Pharmacopoeial monograph. The test was carried out using Tablet disintegration 
apparatus. 
Six tablets from each batch were placed and one liter of distilled water was 
used as the disintegration medium. The time required to obtain complete 
disintegration of all the six tablets was noted. 
 
(III) In – Vitro Dissolution Studies  
In-vitro drug release studies for the Oro dispersible tablets of Diltiazem 
hydrochloride  was studied using Dissolution apparatus II USP XX1 model 
[Paddle type] for the fabricated batches. 650ml of sorenson’s buffer solution [pH 
6.8] was used as the dissolution medium. The tablet was placed in the dissolution 
medium and rotated at a speed of 50 rpm maintained at a temperature of 37   
0.5oC. 
1ml of sample was withdrawn at periodic intervals 1st, 2nd, 4th, 6th, 8th and 
10th minutes and was made upto 10ml with sorenson’s buffer solution. 1ml of 
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fresh dissolution medium [maintained at the same temperature] was replaced after 
each time of withdrawal of samples. 
The samples were analyzed spectrophotometrically at 237 nm for the drug 
content against the respective buffer blank. The mean percentage of Diltiazem 
hydrochloride  released at various time intervals was calculated from standard 
graph and plotted against time. 
 
5.5  Comparative In – Vitro Drug Release Studies For The Optimizied 
Formulation F8 [CP-10%] With Marketed Diltiazem hydrochloride  
Tablets29. 
  Compare the drug release rates of the fabricated Oro dispersible tablets 
[CP – 10%] with that of the commercially available tablets of Diltiazem 
hydrochloride  DILZEM  [Torrent] was selected as a choice and dissolution 
studies were carried out. 1ml sample were withdrawn periodically and proceeded 
for the previous mentioned standard analysis by UV – method. 
 
5.6 Stability Studies 
Stability studies were carried out for the optimized formulation F8 [CP-
10%].  The samples were packed in an aluminum foil placed in an tightly closed 
plastic container and kept at 4oC in refrigerator, 40oC / 75% RH in stability 
chamber [osworld, Mumbai] and 60oC in Incubator for 1 month according to ICH 
guidelines. At the interval of 15 days, the tablets were withdrawn and evaluated 
for Thickness, Diameter, Hardness, Friability, weight variation, content 
uniformity and disintegration time. 
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The In-vitro dissolution study was carried out for 3 month at the interval of 
1 month. 
5.7  Kinetics of Drug release 
The optimized formulation F8 [CP -10%] was subjected to kinetic 
treatment to assess the order of drug release. 
A plot of Logarithm of percentage of drug remaining to be released versus 
time would be linear if the rate of drug release follows First order kinetics 
The linear equation for first order drug release plot is 
log C = Log Co  – 
303.2
Kt  
C = concentration remaining at time ‘t’ 
Co = original concentration 
t = time 
k = release rate. 
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6. RESULTS AND DISCUSSION 
 
Pre Formulation Studies  
1. Drug – Excipients compatibility studies  
 Diltiazem hydrochloride  was subjected to Drug – Excipients compatibility studies 
with various excipients like cros povidone, cros carmellose sodium, sodium starch glycolate, 
povidone, microcrystalline cellulose, Mannitol, Magnesium stearate, Saccharin sodium and 
colloidal silicon dioxide. The mixtures have shown no colour change.  
2. Angle of repose  
 The angle of repose for the powder blends of all batches exhibits good flow 
properties.  
3. Loss on Drying  
 The moisture content has influence on tableting process in various aspects like 
sticking and also affect the moisture sensitive excipients like povidone, cros povidone, cros 
carmellose sodium and sodium starch glycolate.  
 The loss on drying for various batches of powder blends varies from 1.53 to 2.09. 
Hence excipient like Colloidal silicon dioxide [Aerosil] was selected to maintain the moisture 
content.  
4. Bulk Density, Tapped Density, Hausner Ratio and Carr’s Index  
 Bulk Density, Tapped Density, Hausner Ratio and Carr’s Index were studied. From 
the obtained Bulk density and Tap density values Hausner ratio and Carr’s index were 
calculated. Since the Hausner ratio was less than 1.25% for all batches of powder blends, the 
flow property was good. Also the Carr’s index was below 15% for all batches of powder 
blends, the flow property was good.  
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The results for Angle of repose, Loss on Drying, Bulk Density, Tapped Density, 
Hausner ratio and Carr’s Index were predicted in Table.4.  
TABLE : 8.  PHYSICAL CHARACTERISTICS OF POWDER BLENDS 
 
 
 
 
 
Sl. 
No Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Bulk density (g/ml) 0.580.37 
0.58

0.54 
0.58

0.26 
0.56

0.91 
0.56

0.36 
0.56

0.41 
0.55

0.39 
0.55

0.98 
0.55

0.75 
2 Tapped density(g/ml) 
0.643

0.035 
0.649

0.04 
0.646

0.09 
0.646

0.08 
0.646

0.19 
0.647

0.03 
0.634

0.04 
0.636

0.05 
0.634

0.03 
3 Hausner ratio 
1.106
 0.24 
1.111

0.57 
1.107

0.39 
1.147

0.18 
1.152

0.28 
1.152

0.36 
1.144

0.18 
1.156

0.17 
1.143

0.11 
4 Carr’s index (%) 9.630.35 
10.02

0.41 
9.69

0.87 
12.84

1.12 
13.24

1.06 
13.22

0.78 
12.59

0.67 
.13.50

0.81 
12.55

0.59 
5 Angle of repose ( ) 23o.83 0.35 
23o.12

0.41 
23o.61

0.68 
22o.20

0.69 
22o.05

0.39 
22o.31

0.38 
21o.20

0.31 
21o.32

0.64 
21o.53

0.36 
6 Loss on drying 1.970.18 
1.86

0.25 
1.89

0.05 
1.82

0.09 
1.76

0.11 
1.77

0.07 
2.32

0.03 
2.41

0.01 
2.38

0.28 
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TABLE NO: 9. PHYSICAL CHARACTERISTICS OF GRANULES 
 
Sl 
No 
Parame
ters F 1 F 2 F 3 F4 F 5 F6 F 7 F 8 F9  
1 Bulk 
density 
(g/ml) 
0.58
0.38 
0.60
0.58 
0.59
0.64 
0.59
0.43 
0.58
0.26 
0.56  
0.61 
0.55
0.65 
0.57
0.39 
0.58
0.61 
2 Angle 
ofrepose 
(0)  
28.2 
 0.03  
29.3 
  0.15  
29.3  
 0.04  
27.3  
  0.30  
30.2 
  
0.900  
28.5 
  0.910 
26.2  
  0.32  
25.3 
  0.412  
28.1 
  0.412 
3 Tap 
density 
(g/ml) 
0.69
0.02 
0.68
0.09 
0.67
0.12 
0.66
0.007 
0.68
0.08 
0.65
0.06 
0.64
0.07 
0.66
0.009 
0.65
0.05 
4.  carr’s 
index  
14.7
0.34 
13.6
0.29 
14.9
0.61 
13.63
0.24 
14.7
0.31 
13.9
0.48 
14.5
0.48 
13.6
0.42 
13.8
0.17 
5.  Hausner 
ratio  1.18
0.12 
1.14
0.18 
1.3
0.36 
1.15
0.54 
1.17
0.15 
1.16
0.18 
1.16
0.21 
1.16
0.34 
1.15
0.14 
 
5. Infra Red Spectroscopic Studies  
 By using FT IR technique, Diltiazem hydrochloride and superdisintegrants such as 
crospovidone, croscarmellose sodium, sodium starch glycolate and povidone were identified 
by the frequency of the obtained peaks.  
 
 The Interpretation of the Infrared spectrum of the drug and superdisintegrants are as 
follows. 
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Table : 10.  IR Spectra of Diltiazem hydrochloride   
Frequency cm-1 Groups Assigned 
3034 Aromatic C – H stretching 
3005 Aliphatic C – H stretching 
2842 O – CH3 C-H stretching 
2388 Amine HCl N – H stretching 
1743 Acetate C = O stretching 
1678 Lactam C = O stretching 
1606 C = O stretching 
1474 C – H bending 
837 O – substituted aromatic C – H out of 
plane deformation 
777 P – substituted aromatic C – H out of 
plane deformation 
 
Table : 11  IR Spectra of  formulation  
Frequency (cm-1) Groups Assigned 
3005 Aliphatic C – H stretching 
2842 O – CH3 C-H stretching 
2388 Amine HCl N – H stretching 
1743 Acetate C = O stretching 
1678 Lactam C = O stretching 
1606 C = O stretching 
1474 C – H bending 
837 O – substituted aromatic C – H 
out of plane deformation 
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Fig : 6  IR Spectra of Diltiazem hydrochloride   
 
Fig : 7  IR Spectra of  formulation 
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EVALUATION OF FABRICATED TABLETS 
a) Thickness, Diameter and Hardness 
 The Thickness and Diameter of the tablets were found in the range of 3.09  0.08 to 
3.31   0.21 and 7.89   0.08 to 8.11   0.12. The Hardness of the different formulations 
ranged from 3.8 to 3.9 Kg/cm2. 
Table : 12. Thickness, Diameter and Hardness data of the tablets   
Formulation 
Code 
Batch Thickness(mm) 
  S.D [n=5]  
Diameter(mm) 
  S.D [ n = 5] 
Hardness[Kg/cm2] 
  S.D [ n = 5] 
F1 SSG – 5% 3.14   0.09 8.11   0.20 3.8  0.32 
F2 SSG – 10% 3.18   0.12 8.02   0.49 3.8   0.64 
F3 SSG – 15% 3.19   0.18 7.96   0.52 3.9   0.71 
F4 CCS – 5% 3.21  0.09 7.92   0.62 3.8 0.47 
F5 CCS – 10% 3.20   0.22 8.03   0.81 3.8   0.39 
F6 CCS  15% 3.18   0.19 8.02   0.3 3.8  0.62 
F7 CP -5% 3.22   0.40 7.98   0.32 3.9   0.81 
F8 CP – 10% 3.26    0.36 7.91   0.14 3.9   0.76 
F9 CP – 15% 3.30   0.28 8.03   0.32 3.9   0.82 
 
b) Friability and Weight Variation Test 
 Depending upon the ingredients of different formulations, the weight of tablet was 
fixed. In each formulation, weight variation was within the I.P. Limit. Mostly the variation 
was within  1%. All the formulations exhibited less than 1% Friability and was within the 
I.P. Limit.  
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Table : 13.  Friability and Weight Variation Data of the Tablets.  
 
Formulation 
Code Batch Friability (%) 
WeightVariation(mg)
S.D 
F1 SSG – 5% 0.383 249.75  1.10 
F2 SSG – 10% 0.387 249.85   0.48 
F3 SSG – 15% 0.372 249.10   0.62 
F4 CCS – 5% 0.361 249.85   0.67 
F5 CCS – 10% 0.351 249.37   0.38 
F6 CCS  15% 0.361 249.80   0.45 
F7 CP -5% 0.382 249.60   0.67 
F8 CP – 10% 0.441 250.12   1.18 
F9 CP – 15% 0.421 250.03   1.18 
 
c) Wetting Time and Water Absorption Ratio  
 The results of Wetting time and Water absorption ratio are presented in Table.14. The 
Wetting time ranges from 9.76 sec [CP-15% ] to 13.78 [SSG-10% ] sec and water absorption 
ratio ranges from 69.13[CP-5% ]  to 84.42 [SSG-15% ] 
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Table: 14. Wetting Time and Water Absorption Ratio Data of the Tablets 
Formulation 
Code Batch Wetting Time [sec]  
Water Absorption 
Ratio 
F1 SSG – 5% 12.02   0.23 80. 56 
F2 SSG – 10% 13.78   0.32 80.83 
F3 SSG – 15% 12.39   0.27 81.42 
F4 CCS – 5% 11.16   0.04 76.25 
F5 CCS – 10% 11.11  0.02 75.79 
F6 CCS –  15% 11.16   0.08 74.52 
F7 CP -5% 9.87     0.01 69.41 
F8 CP – 10% 9.84    0.15 69.13 
F9 CP – 15% 9.96   0.01 69.16 
 
FIG.8. DETERMINATION OF WETTING TIME OF VARIOUS FORMULATIONS 
OF ODT’s OF DILTIAZEM HYDROCHLORIDE         
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d ) Test for Uniformity of Dispersion  
 The results of Test For Uniformity of Dispersion are presented in Table : 13  
 
Table : 15  Uniformity of Dispersion Data of Tablets  
Formulation 
Code Batch 
Residue remaining on 
Screen Result 
F1 SSG – 5% NIL PASS 
F2 SSG – 10% NIL PASS 
F3 SSG – 15% NIL PASS 
F4 CCS – 5% NIL PASS 
F5 CCS – 10% NIL PASS 
F6 CCS – 15% NIL PASS 
F7 CP–  5% NIL PASS 
F8 CP – 10% NIL PASS 
F9 CP – 15% NIL PASS 
0
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All batches of tablets  posses good uniformity of dispersion. 
 
e ) Test for Uniformity of Drug Content  
 The content uniformity test for Diltiazem hydrochloride  was carried out. The results 
was found to be 99.98  0.071% [SSG – 10%]  to 100.01   0.21% [CCS – 5%]. The results 
were found to be within the I.P. Limits [90%-110%]. It shows that the drug was distributed 
uniformly throughout the tablets.  
 
 
Table : 16  Uniformity of Drug content Data of the Tablets.  
Formulation 
Code 
Batch Drug Content 
(%)  S.D 
No.of Tablets Outside 
90% – 110% Limit 
F1 SSG – 5% 99.97   0.069 NIL 
F2 SSG – 10% 99.99   0.074 NIL 
F3 SSG – 15% 99.98   0.12 NIL 
F4 CCS – 5% 100.01   0.20 NIL 
F5 CCS – 10% 100.01   0.14 NIL 
F6 CCS  15% 99.99   0.08 NIL 
F7 CP -5% 99.98   0.03 NIL 
F8 CP – 10% 99.99   0.06 NIL 
F9 CP – 15% 100.01   0.03 NIL 
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f) Moisture Uptake by Various Formulations of Oro dispersible  Tablets: (ODT’s) 
 The moisture uptake test was conducted for various formulations of Oro dispersible  
tablets of Diltiazem hydrochloride. Any difference in moisture uptake among various 
formulations may be due to difference in type or concentration of super disintegrant added.  
 From the observations, it is evident that water uptake of super disintegrant follows the 
order SSG > CCS > CP.  
 
 (j) IN – VITRO DRUG RELEASE STUDIES  
(I) & (II)  In – vitro Dispersion Time and In – vitro Disintegration Time  
 The results of In-vitro dispersion time and In-vitro disintegration time ranges from 
8.79 sec [CP –5%] to 13.49 sec [PVP–15%] and 10.04 sec [CP – 15%] to 17.31 sec [PVP–
15%]  
Table: 17. In-vitro Dispersion Time and In-vitro Disintegration Time Data of the tablets 
Formulation 
Code 
Batch In-Vitro Dispersion 
Time (sec)   S.D  
[n = 3] 
In-vitro Disintegration 
Time (sec)   S.D. [n=6] 
F1 SSG – 5% 11.16   0.13 13.82   0.11 
F2 SSG– 10% 11.27   0.06 13.79    0.13 
F3 SSG– 15% 11.38   0.01 13.80   0.18 
F4 CCS – 5% 9.01   0.02 12.08   0.14 
F5 CCS–10% 10.06   0.01 12.19   0.19 
F6 CCS–15% 10.19   0.04 12.21   0.12 
F7 CP –5% 8.79   0.06 10.10   0.02 
F8 CP – 10% 8.91   0.03 10.08   0.21 
F9 CP – 15% 8.94   0.08 10.04   0.04 
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Analysis of Samples : 
 
 1ml of sample was withdrawn at periodic intervals 1st, 2nd, 4th, 6th, 8th and 10th minutes 
and was made up to 10ml with Sorenson’s buffer solution. 1ml of Fresh dissolution  medium 
was replaced after each time of withdrawl of sample. The samples were analyzed spectro 
photometrically at 228 nm for the drug content against the respective buffer blank. The mean 
percentage of Diltiazem hydrochloride  released at various time intervals was calculated and 
plotted against time.  
 
 The results of the dissolution data for various formulations of ODT’s of Diltiazem 
hydrochloride  are presented in Table 17 to 28.  
 
In – vitro Dissolution Studies  
Table : 17  Dissolution data of F1 [SSG-5%]  
Sl.No Time in min Amount of drug release in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 18.2 60.61 60.61 
2 2 18.32 63.07 63.16 
3 4 21.45 71.5 71.60 
4 6 22.10 73.67 73.78 
5 8 24.05 80.14 80.25 
6 10 24.05 81 81.12 
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Fig.6: Dissolution Profile of Formulation F1 [SSG-5%] 
                         
  Table : 18 Dissolution data of F2 [SSG -10%] 
Sl.No Time in min Amount of drug release in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 18.92 
63.07 63.07 
2 2 20.8 
69.33 69.43 
3 4 22.1 
73.67 73.78 
4 6 23.4 
78 78.11 
5 8 24.7 
82.35 82.47 
6 10 25.35 
84.5 84.63 
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Fig.7: Dissolution Profile of Formulation F2 [SSG-10%] 
 
Table : 19  Dissolution data of F3 [SSG -15%] 
Sl.No Time in min Amount of drug release in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 21.45 71.5 71.5 
2 2 22.1 73.67 73.78 
3 4 24.05 80.17 80.28 
4 6 25.02 83.42 83.54 
5 8 26.65 89.83 89.96 
6 10 27.63 92.1 92.24 
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Fig.8 Dissolution Profile of Formulation F3  [SSG-15%] 
 
Table : 20 Dissolution data of F4 [CCS -5%] 
Sl.No Time in min Amount of drug release in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 20.8 69.33 69.33 
2 2 22.6 73.67 73.78 
3 4 24.05 80.17 80.28 
4 6 25.35 84.5 84.62 
5 8 26.97 89.91 90.04 
6 10 27.63 92.1 92.24 
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Fig.9: Dissolution Profile of Formulation F4 [CCS-5%] 
 
Table : 21 Dissolution data of F5 [CCS -10%] 
 
Sl.No Time in min 
Amount of drug 
release in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 21.77 72.58 72.58 
2 2 24.05 80.17 80.28 
3 4 25.35 84.5 84.62 
4 6 27.3 91 91.13 
5 8 27.95 93.16 93.30 
6 10 28.6 95.33 95.47 
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Fig.10: Dissolution Profile of Formulation F5 [CCS-10%] 
 
Table : 22 Dissolution data of F6 [CCS-15%] 
Sl.No Time in min Amount of drug release in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 23.4 78 78 
2 2 25.35 84.5 84.62 
3 4 26 86.67 86.80 
4 6 27.63 92.1 92.23 
5 8 28.6 95.33 95.47 
6 10 29.25 97.5 97.65 
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Fig.11: Dissolution Profile of Formulation F6 [CCS-15%] 
 
Table : 23 Dissolution data of F7 [CP-5%] 
Sl.No Time in min Amount of drug release in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 24.37 81.25 81.25 
2 2 25.35 84.5 84.62 
3 4 26.97 89.91 90.04 
4 6 28.27 94.25 94.39 
5 8 28.92 96.41 96.55 
6 10 29.25 97.5 97.65 
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Fig.12 : Dissolution Profile of Formulation F7 [CP-5%] 
 
Table : 24 Dissolution data of F8 [CP-10%] 
Sl.No Time in min Amount of drug release in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 24.37 
81.25 81.25 
2 2 25.35 
84.5 84.62 
3 4 26.65 
88.43 88.56 
4 6 27.95 
93.16 93.30 
5 8 29.25 
97.5 97.64 
6 10 29.9 
99.66 99.81 
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Fig.13 : Dissolution Profile of Formulation F8 [CP-10%] 
 
Table : 25  Dissolution data of F9 [CP-15%] 
Sl.No Time in min 
Amount of drug 
release in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 23.7 
79.08 79.08 
2 2 25.02 
83.42 83.54 
3 4 26 
86.67 86.80 
4 6 27.3 
91 91.13 
5 8 27.95 
93.16 93.30 
6 10 28.92 
96.41 96.55 
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Fig.14 : Dissolution Profile of Formulation F9 [CP-15%] 
 
Formulation F1[SSG-5%], F2[SSG-10%] and F3[SSG-15%] 
 Formulation F1, F2 and F3 releases 81.12%, 84.63% and 92.24% drug respectively at 
the end of 10 minutes. The percentage of drug release increased with increased concentration 
of Sodium Starch Glycolate (SSG) from 5 to 15%.  
 The higher dissolution rates observed with SSG may be due to rapid disintegration 
and fine dispersion of particles formed after disintegration.  
 
Formulation F4[CCS-5%], F5[CCS-10%] and F5[CCS-15%] 
 Formulation F4, F5 and F6 release 92.24%, 95.47% and 97.65% respectively at the end 
of 10 minutes. The percentage of drug release increased with increased Concentration of Cros 
Carmellose Sodium (CCS) from 5 to 15%.  
 The higher dissolution rates observed with CCS may be due its strong swelling power 
which exerts sufficient hydrodynamic pressure which inturn facilitates complete and rapid 
disintegration.  
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Formulation F7[CP-5%], F8[CP-10%] and F9[CP-15%] 
 Formulations F7, F8, and F9 releases 97.65%, 99.81% and 96.55% drug respectively at 
the end of 10 minutes [Ref.Table 23 – 25, Fig 12 - 14 ]  
 The percentage of drug release increased with increased concentration of 
superdisintegrant. From 5 to 10% on increasing the concentration of superdisintgrant from 10 
to 15%. The percentage of drug release declines.  
 In case of polyplasdone XL [CP] up to 10% w/w concentration, there was steady 
increase dissolution rate with concentration. Therefore 10% w/w concentration is optimum 
for polyplasdone XL [CP].  
 The higher dissolution rates observed upto the optimum concentration [10% w/w] 
may be due to highly porous structure of the super disintegrant which facilitates faster water 
uptake and hence faster disintegration, easy break down of particles and rapid absorption of 
drug into the dissolution medium.  
 Decrease in dissolution rate with increase in concentration may be due to the blockade 
of pores resulting in interior of tablets inaccessible to water.20  
 
 
Order of Enhancement of  Dissolution rate with Various Super disintegrants 
 In the formulation of ODT’s of Diltiazem hydrochloride  various super disintegrants 
like Cros Povidone [CP], Cros Carmellose Sodium [CCS] and Sodium Starch Glycolate 
[SSG] were employed.  
 The order of enhancement of the dissolution rate with various super disintegrants was 
found to be CP > CCS > SSG.  
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 From the overall observations, formulation F8 containing 10%w/w concentration of 
Cros povidone was considered to be the optimized formulation which releases upto 99.81% 
of the drug in ten minutes.  
 (V) Comparative In-vitro Drug Release Studies for the Optimized Formulation F8 [Cp – 
10%] With Marketed Sample of  the Same Drug [Suminat]  
 The In-vitro Drug release profiles for the optimized formulation F8[CP-10%] was 
compared with Dilzem [Torrent] 
 At the end of ten minutes of  in-vitro dissolution study only 48.49% of the drug was 
released from Dilzem whereas 99.81% of the drug was released from the optimized 
formulation F8 [CP-10%]. 
 
 Table : 30 In-vitro Dissolution data for Dilzem 
Sl.No Time in min 
Cumulative % drug release 
F8 Marketted product 
1 1 81.25 12.35 
2 2 84.62 19.28 
3 4 88.56 31.14 
4 6 93.30 38.24 
5 8 97.64 43.85 
6 10 99.81 48.49 
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Fig.19 : Dissolution Profile of Formulation F8 [ CP-10 %]  
compared with Dilzem 
 
The results obtained from the data given in Table.28 reveals that enhanced dissolution 
characteristics of the formulation F8[CP-10%] which may be due to the high wicking action 
of Cros Povidone which makes the tablets to swell and facilitates quick disintegration of the 
tablets.  
 
(VI) Stability Studies  
 The optimized formulations F8[CP-10%] was subjected to stability studies for  3 
month at 40oC / 75% RH in stability chamber [Osworld, Mumbai], 8oC in Refrigerator and 
60oC in Incubator. At the interval of 30 days, the tablets were withdrawn and evaluated for 
Thickness, Diameter, Hardness, Friability, weight variation, content uniformity and 
disintegration time. All the parameters have not shown much variation when compared to the 
initial data and the results were within the limits.  
 The in-vitro dissolution studies were carried out for 3 months at the interval of 30 
days. The release profiles were not affected by exposing to higher temperature and the 
specified humidity conditions.  
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Table : 31 Dissolution data of F8 A.S [CP – 10%] [After 1 month  at 4oC] 
Sl.No Time in min 
Amount of drug 
release in mg 
Percentage 
drug 
release 
(%) 
Cumulative % 
drug release 
1 1 24.37 81.25 81.25 
2 2 25.35 84.5 84.62 
3 4 26.65 88.43 88.56 
4 6 27.95 93.16 93.30 
5 8 29.25 97.5 97.64 
6 10 29.9 99.66 99.81 
 
 
Fig.20: Dissolution profile of F8 A.S [CP – 10%] [After 1 month at 4oC] 
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Table :  32  Dissolution data of F8 [CP – 10%] [After 2 month at 4oC] 
Sl.No Time in min Drug concentration in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 24.37 81.25 81.25 
2 2 25.35 84.5 84.62 
3 4 26.65 88.43 88.56 
4 6 27.95 93.16 93.30 
5 8 29.25 97.5 97.64 
6 10 29.9 99.66 99.81 
 
 
Fig.21:Dissolution profile of F8 A.S [CP – 10%] [After  2 months at 4oC] 
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Table : 33  Dissolution data of F8[CP 10%] [After 3 months at 4oC] 
Sl.No Time in min Drug concentration in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 24.37 
81.23 81.23 
2 2 25.35 
84.50 84.62 
3 4 26.00 
86.66 86.79 
4 6 28.60 
95.33 95.46 
5 8 29.25 
97.50 97.65 
6 10 29.90 
99.67 99.82 
 
 
Fig.22:Dissolution profile of F8 A.S [CP – 10%] [After 3 months at 4oC] 
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Table : 34  Dissolution data of F8[CP -10%] [After 1 month at room temperature] 
Sl.No Time in min Drug concentration in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 24.37 81.25 81.25 
2 2 25.35 84.5 84.62 
3 4 26.65 88.43 88.56 
4 6 27.95 93.16 93.30 
5 8 29.25 97.5 97.64 
6 10 29.9 99.66 99.81 
 
 
Fig.23:Dissolution profile of F8 A.S [CP – 10%] [After 1 month at room temperature] 
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Table : 35  Dissolution data of F8[CP – 10%] [After 2 months at room temperature]  
Sl.No Time in min Drug concentration in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 24.37 81.23 81.23 
2 2 25.35 84.50 84.62 
3 4 26.65 88.43 88.56 
4 6 27.30 91.00 91.14 
5 8 28.60 95.33 95.47 
6 10 29.90 99.67 99.82 
 
 
Fig.24:Dissolution profile of F8 A.S [CP – 10%] [After 2 months at room temperature] 
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Table : 36  Dissolution data of F8[CP – 10%] [After 3 months at room temperature] 
Sl.No Time in min Drug concentration in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 23.40 78.00 78.00 
2 2 25.35 84.50 84.62 
3 4 26.00 86.67 86.80 
4 6 27.30 91.00 91.13 
5 8 29.25 97.50 97.64 
6 10 29.90 99.67 99.82 
  
 
Fig.25:Dissolution profile of F8 A.S [CP – 10%] [After 3 months at room temperature] 
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Table : 37  Dissolution data of F8[CP – 10%] [After 1 month at 45oC/ 75%RH] 
Sl.No Time in min Drug concentration in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 23.40 78.00 78.00 
2 2 25.35 84.50 84.62 
3 4 26.65 88.43 88.56 
4 6 27.30 91.00 91.14 
5 8 28.60 95.33 95.47 
6 10 29.90 99.66 99.80 
  
 
Fig.26:Dissolution profile of F8 A.S [CP – 10%] [After 1 month at 45oC/ 75%RH] 
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Table : 38  Dissolution data of F8[CP – 10%] [After 2 months at 45oC/ 75%RH] 
Sl.No Time in min Drug concentration in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 22.75 75.80 75.80 
2 2 24.70 82.33 82.44 
3 4 26.00 86.67 86.80 
4 6 27.30 91.00 91.13 
5 8 28.60 95.33 95.47 
6 10 29.57 98.58 98.73 
     
 
 
Fig.27:Dissolution profile of F8 A.S [CP – 10%] [After 2 months at 45oC/ 75%RH] 
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Table : 39  Dissolution data of F8[CP – 10%] [After 3 months at 45oC/ 75%RH] 
Sl.No Time in min Drug concentration in mg 
Percentage 
drug release 
(%) 
Cumulative % 
drug release 
1 1 22.75 75.80 75.80 
2 2 24.05 80.17 80.29 
3 4 25.35 84.50 84.62 
4 6 26.65 88.43 88.56 
5 8 27.95 93.16 93.30 
6 10 29.25 97.50 97.64 
 
 
Fig.28:Dissolution profile of F8 A.S [CP – 10%] [After 3 months at 45oC/ 75%RH] 
The optimized formulation F8 did not show any significant changes in drug release 
profile, hardness, friability, weight variations after the period of 3 months. Hence it can be 
concluded that the optimized batch F8 is stable at an accelerated storage conditions. 
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KINETICS OF DRUG RELEASE 
A plot of percentage of drug remaining verses time would be linear. If the drug 
release follows zero order kinetics [i.e. concentration independent release]. 
         The linear equation for zero order drug release plot is. 
 
                              Ct = C0 – Kt 
Where 
           Ct= concentration remaining at time t. 
           C0= Original concentration. 
T = Time. 
           K = Release rate.  
 
A  plot of log concentration of drug remaining verses time would be linear, if the drug 
release follows first order kinetics [i.e. concentration dependent]. 
 The linear equation for first order drug release plot is. 
 
    Log C = Log C0 – Kt/2.303 
 
Since the polymers used for preparing Oro dispersible tablets are soluble in the 
medium, was assumed that the drug release data obtained in dissolution for optimized 
formulation was treated accordingly to first order equation. 
The optimized formulation F8 [CP -10%] upon kinetic treatment releases the drug by 
first order kinetics. 
 A plot of Logarithm of percentage of drug remaining to be released versus time 
showed linearity.From the plot, correlation coefficient and slope value was found to be 0.857. 
              The values obtain signify that the drug release follows first order kinetics (i.e.   
concentration dependent release).  
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Fig.29: Plot of Log % of Drug remaining to be released Versus Time IN F8 
 
 
Fig 30 Plot Of  Zero Order Drug Release In F8 
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FIG NO 31 PLOT OF HIGUCHI IN F8 
 
 
 
FIG 32. PLOT OF PEPPA’S IN F8 
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Discussion on kinetic studies: 
To know the drug release from the formulation F9, data obtained from the in-vitro 
dissolution studies was fitted into Zero order, First order, Higuchi, Korsmeyer-peppas 
equations. 
 
First order kinetics plot:  
The graph was plotted between log cumulative % drug remaining and time. 
Formulation F9 was best explained by first order kinetics and regression value is 0.857 
showed that drug release relationship with concentration of the drug.  
 
Zero order kinetics plot:  
The graph was plotted between  cumulative % drug release and time. Formulation F9 
was best explained by first order kinetics and regression value is 0.596 showed that drug 
release doesn’t relationship with concentration of the drug.  
 
Higuchi plot:  
       The graph was plotted between cumulative % drug remaining and square root of time. 
The regression value is 0.883 that clearly indicating that drug releasing mechanism was 
predominantly controlled by Diffusion mechanism.  
 
Korsmeyer - peppas plot: 
       The graph was plotted between log cumulative % of drug remaining and log time. The 
regression value was 0.674. This indicates the drug release follow fickian diffusion. 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
 
 The oro dispersible Tablets (ODT’s) of Diltiazem hydrochloride  were prepared by 
Direct compression method using various super disintegrants.  Formulation F8 containing 
10%w/v concentration of Cros Povidone with appropriate amount of other excipients were 
considered  to be the optimized formulation with the desired drug release.  
 
The oro dispersible Tablet formulation of Diltiazem hydrochloride provides instant 
relief for migraine sufferers and helps them to resume their normal function as soon as 
possible. All formulation were found to have homogenic drug distribution with excellent  
content uniformity. F8 batch contains 10% CP was optimized. 
 
          Comparative drug release study revealed that the formulated Oro dispersible tablets 
[ODT’s] release drug more rapidly than the marketed sample.  
 
           The results of stability studies revealed that the formulation F8 showed no significant 
variations in all the parameters and was stable for a period of 3 months. 
 
           The optimized formulation F8 was found to follow First order kinetics, which was 
revealed by the linearity shown from the plot of logarithm of drug remaining to be released 
versus time.  
In future, the developed formulation F8 can be subjected to Bioequivalence study and 
suitability to the market can be decided based on that.  
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